| x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|--------------------------------------------------------------------------------------|

|  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|------------------------------------------------------------------------------------------|

----

ANIMAL HEALTH INTERNATIONAL, INC.

----

| Delaware                                                      |   | 71-0982698                             |
|---------------------------------------------------------------|--------|----------------------------------------|
| (State or other jurisdiction ofincorporation or organization) |   | (I.R.S. EmployerIdentification Number) |
|                                                          |   |
| 7 Village Circle, Suite 200Westlake, Texas                    |   | 76262                                  |
| (Address of principal executive offices)                      |   | (Zip Code)                             |

----

| Title of each class           |   | Name of Each Exchange on Which Registered |
|-------------------------------|--------|-------------------------------------------|
| Common Stock, $0.01 par value |   | The NASDAQ Stock Market, LLC         |

----

| Large Accelerated Filer o | Accelerated Filer   o | Non-Accelerated Filer   o           | Smaller Reporting Company   x |
|---------------------------|---------------------------------|-----------------------------------------------|----------------------------------------------|
|                      |                            | (Do not check if a smaller reporting company) |                                         |

----

TABLE OF CONTENTS

|     |         |                                                                                                        |         |   |
|----------|--------------|-------------------------------------------------------------------------------------------------------------|--------------|--------|
| Item     |    | Description                                                                                            |    | Page   |
| PART I   |
|     |         |                                                                                                        |
| 1.       |    | Business                                                                                                    |    | 1      |
| 1A.      |    | Risk Factors                                                                                                |    | 11     |
| 1B.      |    | Unresolved Staff Comments                                                                                   |    | 23     |
| 2.       |    | Properties                                                                                                  |    | 23     |
| 3.       |    | Legal Proceedings                                                                                           |    | 23     |
| 4.       |    | Submission of Matters to a Vote of Security Holders                                                         |    | 23     |
|     |
| PART II  |
|     |         |                                                                                                        |
| 5.       |    | Market for AHI’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities |    | 24     |
| 6.       |    | Selected Financial Data                                                                                     |    | 26     |
| 7.       |    | Management’s Discussion and Analysis of Financial Condition and Results of Operations                 |    | 29     |
| 7A.      |    | Quantitative and Qualitative Disclosures About Market Risk                                                  |    | 39     |
| 8.       |    | Financial Statements and Supplementary Data                                                                 |    | 39     |
| 9.       |    | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure                        |    | 39     |
| 9A.      |    | Controls and Procedures                                                                                     |    | 39     |
| 9B.      |    | Other Information                                                                                           |    | 40     |
|     |
| PART III |
|     |         |                                                                                                        |
| 10.      |    | Directors, Executive Officers and Corporate Governance                                                      |    | 41     |
| 11.      |    | Executive Compensation                                                                                      |    | 41     |
| 12.      |    | Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters              |    | 41     |
| 13.      |    | Certain Relationships, Related Transactions and Director Independence                                       |    | 41     |
| 14.      |    | Principal Accounting Fees and Services                                                                      |    | 41     |
|     |
| PART IV  |
|     |         |                                                                                                        |
| 15.      |    | Exhibits and Financial Statement Schedules                                                                  |    | 42     |

----

PART I

| Item 1. | Business. |
|--------------|-----------|

----

Pharmaceuticals. Pharmaceuticals include dosage form medicines employed in disease prevention and treatment programs. Pharmaceuticals such as antibiotics, anthelmintics, insecticides and implants include both over-the-counter products, which can be sold directly toend-users, and ethical products, which are sold to, or through, veterinarians.

|   | • |   | Antibiotics are administered for the treatment and prevention of diseases such as chronic respiratory disease and for growth promotion. Antibiotics include products such as tetracyclines, penicillins, erythromycins, cephalosporins and fluroquinolones. Antibiotics are available in injectable, bolus (i.e. pill), additive and drench (i.e. liquid)forms. |
|--------|---------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | Anthelmintics are deworming agents administered on a routine basis to animals for the prevention and treatment of internal parasites and worms in production animals. Worms include gastrointestinal roundworms, stomach worms, intestinal worms and lungworms. Anthelmintics are available in injectable, bolus, drench, additive, pour-on and pasteforms. |
|--------|---------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | Insecticides are used to control insect populations on animals and their premises, and are administered on a routine, preventative basis. Insecticides can be used to control flies, lice, ticks, mites and fleas, and are available in dust, liquid, spray and ear tag forms. Endectocides are active against both internal and external parasites andhence are both an anthelmintic and an insecticide. |
|--------|---------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | Implants are used for the promotion of growth in animals, to increase weight gain and improve yield in cattle. |
|--------|---------|--------|----------------------------------------------------------------------------------------------------------------|

----

----

of net sales. We have over 31,000 accounts served directly by our sales force and approximately 40,000 additional accounts that are served by Internet and catalog sales. Our customers range in size from single-practitioner veterinarians to large, corporate cattle feeding operations. Due to longstanding relationships between our sales force and our customers, 76% of our top 500 customers that placedorders with us in 2002 still order from us today.

|   | • |   | Cow/Calf.According to the United States Department of Agriculture (USDA), this sub-group is extremely fragmented with over 757,000 cattle operations.However, approximately 646,000 operations have 49 or fewer cattle. Calves remain in the cow/calf stage from birth until reaching approximately 400 lbs (roughly six to eight months) at which point they are sold to buying agents and delivered to stocker locations.Per-cattle animal health product spending is approximately $17 during the cow/calf stage. |
|--------|---------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | Stocker. This market consists of operations holding large tracts of land predominantly in the central and western U.S. regions where cattle are moved to graze for roughly three to five months prior to being sold to feedlots. During their stay, cattle increase in weight from 400 lbs to600 lbs. Per-cattle spending is approximately $12 during the stocker stage. |
|--------|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | Feedlots.Feedlots are typically located in the central and western U.S. regionsand hold several thousand to 100,000 cattle in open pens. There are approximately 2,100 feedlots in the United States with capacity greater than 1,000 cattle. Cattle undergo their final growth stage prior to processing and increase in weight from 600 lbs to 1,200 lbs. Length of stay approximates 90 to 120 days and per-cattle spending duringthis stage is approximately $20. Feedlot animal health product requirements mainly consist of de-wormers, growth implants, preventive animal health products (substantially the same products required by cow/calf and stocker customers), acute/chronic disease treatments and medicated additives for growth promotion. |
|--------|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Our livestock products agreement with Pfizer provides that we supply selected customers in the cattle and swine fields with Pfizer products.  In return, we are entitled to certain service fees and rebates. Pfizer is required to indemnify us against any third-party claims for personal injury or property damage arisingout of the distribution or sale of Pfizer products, except in certain circumstances, and any claims alleging that the Pfizer products are defective, except in certain limited situations. Pfizer also reserves the right to sell directly to our customers or any other party. The livestock products agreement has a one-year term that expires on December 31, 2009, and may be terminated by either party with or without cause upon 30 days prior written notice. In addition, either party may terminate the agreementimmediately upon written notice in the event of material breach by the other party.

----

publish monthly reports ranking various metrics and compiling best practices. Several “clubs” such as the Presidents Club are used to distinguish field sales representatives that achieve specific sales targets and maintain high organizational standards.

----

|   | • |   | our strong relationships with leading manufacturers of animal health products; |
|--------|---------|--------|--------------------------------------------------------------------------------|

|   | • |   | our centralized procurement and distribution system that minimizes redundant purchases and inventories; |
|--------|---------|--------|---------------------------------------------------------------------------------------------------------|

|   | • |   | our ability to leverage our fixed cost base; and |
|--------|---------|--------|-------------------------------------------------------|

|   | • |   | our scalable infrastructure. |
|--------|---------|--------|------------------------------|

have access to real-time product data such as inventory quantities (both at our central replenishment and distribution facility and at individual distribution locations), upcoming shipments and timing of deliveries. The system tracks inventory turns at specific distribution locations allowing us to bettermanage the appropriate inventory level for each product at every distribution location. This enables us to move inventory from one distribution center to another as needed.

----

delivery, product selection, market and product knowledge, price and e-commerce capabilities. Some of our competitors, particularly those in the companion animal products market with bigger market share, have greater financial and other resources than we do. Most of our products are available from several sources, including other distributors and manufacturers, and our customers tend to have relationshipswith several distributors. In addition, our competitors could obtain exclusive rights to distribute certain products, eliminating our ability to distribute those products. Consolidation in the animal health products industry could result in existing competitors increasing their market share, which could give them greater pricing power, decrease our revenues and profitability, and increase the competition for customers. See “Risk factors—Risks related to our business—Consolidation in the animalhealth products industry may decrease our net sales and profitability.”

----

----

----

| Item 1A. | Risk Factors. |
|---------------|---------------|

An adverse change in manufacturer rebates or our inability to meet applicable rebate targets has decreased our margins in the past and could continue to materially and negatively affect our business.

----

|   | • |   | Some of our manufacturers are subject to ongoing periodic unannounced inspection by regulatory authorities, including the FDA, the USDA, the EPA, the DEA and other federal and state agencies for compliance with strictly enforced regulations. We do not have control over our manufacturers’ compliance with these regulations and standards.Violations by our manufacturers could potentially lead to interruptions in our supply that could lead to lost sales to competitive products that are more readily available. |
|--------|---------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |    |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|   | • |   | If a purchase order cannot be filled or a certain product line is discontinued or recalled, then we would not be able to continue to offer our customers the same breadth of products. Our sales and operating results would likely suffer unless we were able to find an alternate supply of a similar product. |
|--------|---------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |    |   |                                                                                                                                                                                                                                                                                                             |

|   | • |   | Agreements may commit us to certain minimum purchase levels or other spending obligations. It is possible we will not be able to meet such obligations, which would create an increased drain on our financial resources and liquidity. |
|--------|---------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |    |   |                                                                                                                                                                                                                                    |

|   | • |   | If market demand for our products increases suddenly, our current manufacturers might not be able to fulfill our commercial needs, which may result in substantial delays in meeting market demand. If we generate more demand for a product than one of our manufacturers is capable of handling, we could experience large backorders and potentiallylost sales to competitive products that are more readily available. |
|--------|---------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |    |   |                                                                                                                                                                                                                                                                                                                                                                                                                       |

|   | • |   | We may not be able to control or adequately monitor the quality of products we receive from our manufacturers. Poor quality products could damage our reputation with our customers or subject us to potential legal liability to such customers. |
|--------|---------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|          | • |   | manufacturer rebates based upon attaining certain growth goals;  |
|---------------|---------|--------|------------------------------------------------------------------|
|          |    |   |                                                             |
|          | • |   | changes in the way manufacturers introduce products to market;   |
|          |    |   |                                                             |
|          | • |   | fluctuations in commodity prices;                                |
|          |    |   |                                                             |
|     | • |   | seasonality;                                                     |
|          |    |   |                                                             |
|          | • |   | changes in customer demands;                                     |
|          |    |   |                                                             |
|          | • |   | the impact of general economic trends on our business;           |
|          |    |   |                                                             |
|          | • |   | the recall of a significant product by one of our manufacturers; |
|          |    |   |                                                             |
|     | • |   | changes in climate (e.g., droughts);                             |
|          |    |   |                                                             |
|          | • |   | increases in reserves for bad debts; and                         |
|          |    |   |                                                             |
|          | • |   | competition.                                                     |

  

----

----

|   | • |   | sales and marketing programs; |
|--------|---------|--------|-------------------------------|

|   | • |   | customer service levels; |
|--------|---------|--------|--------------------------|

|   | • |   | current and new product and service lines; |
|--------|---------|--------|--------------------------------------------|

|   | • |   | manufacturer relationships; |
|--------|---------|--------|-----------------------------|

|   | • |   | technological support which equals or exceeds our competitors; |
|--------|---------|--------|----------------------------------------------------------------|

|   | • |   | recruitment and training of new personnel; and |
|--------|---------|--------|------------------------------------------------|

|   | • |   | operational and financial control systems. |
|--------|---------|--------|--------------------------------------------|

----

|   | • |   | make it more difficult for us to satisfy our obligations with respect to our revolving credit facility, term loan indebtedness and other current and future indebtedness; |
|--------|---------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | increase our vulnerability to adverse economic and industry conditions; |
|--------|---------|--------|-------------------------------------------------------------------------|

|   | • |   | require us to dedicate a substantial portion of our cash flow from operations to the payment of our indebtedness, thereby reducing the availability of cash to fund working capital and capital expenditures and for other general corporate purposes; |
|--------|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | restrict us from making strategic acquisitions and exploiting business opportunities; |
|--------|---------|--------|---------------------------------------------------------------------------------------|

|   | • |   | place us at a disadvantage compared to our competitors that have less debt; and |
|--------|---------|--------|---------------------------------------------------------------------------------|

|   | • |   | limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate. |
|--------|---------|--------|----------------------------------------------------------------------------------------------------------------------|

----

|   | • |   | the need to spend substantial operational, financial and management resources in integrating new businesses, technologies and products, and difficulties management may encounter in integrating the operations, personnel or systems of acquired businesses; |
|--------|---------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |    |   |                                                                                                                                                                                                                                                          |

|   | • |   | retention of key personnel, customers and manufacturers of the acquired business; |
|--------|---------|--------|-----------------------------------------------------------------------------------|
|   |    |   |                                                                              |

|   | • |   | the occurrence of a material adverse effect on our existing business relationships with customers or manufacturers, or both, resulting from future acquisitions or business combinations could lead to a termination of or otherwise affect our relationships with such customers or manufacturers; |
|--------|---------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |    |   |                                                                                                                                                                                                                                                                                                |

|   | • |   | impairments of goodwill and other intangible assets; and |
|--------|---------|--------|----------------------------------------------------------|
|   |    |   |                                                     |

|   | • |   | contingent and latent risks associated with the past operations of, and other unanticipated costs and problems arising in, an acquired business. |
|--------|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | • |   | maintenance outages; |
|--------|---------|--------|----------------------|

|   | • |   | prolonged power failures or reductions; |
|--------|---------|--------|-----------------------------------------|

|   | • |   | disruptions in the transportation infrastructure, including railroad tracks, bridges, tunnels or roads; |
|--------|---------|--------|---------------------------------------------------------------------------------------------------------|

|   | • |   | fires, floods, earthquakes or other catastrophic disasters; |
|--------|---------|--------|-------------------------------------------------------------|

|   | • |   | labor difficulties; or |
|--------|---------|--------|------------------------|

|   | • |   | other operational problems. |
|--------|---------|--------|-----------------------------|

Any claims of patent or other intellectual property infringement, even those without merit, could:

|   | • |   | be expensive and time consuming to defend; |
|--------|---------|--------|--------------------------------------------|

|   | • |   | cause us to cease making, licensing or using products or services that incorporate the challenged intellectual property; |
|--------|---------|--------|--------------------------------------------------------------------------------------------------------------------------|

|   | • |   | require us to redesign, reengineer, or rebrand our products or packaging, if feasible; |
|--------|---------|--------|----------------------------------------------------------------------------------------|

|   | • |   | divert management’s attention and resources; or |
|--------|---------|--------|-------------------------------------------------------|

|   | • |   | require us to enter into royalty or licensing agreements in order to obtain the right to use a third party’s intellectual property. |
|--------|---------|--------|-------------------------------------------------------------------------------------------------------------------------------------------|

----

----

|   | • |   | depth and liquidity of the market for our common stock; |
|--------|---------|--------|---------------------------------------------------------|

|   | • |   | investor perception of our business; |
|--------|---------|--------|--------------------------------------|

|   | • |   | profit margins in the animal health products industry generally; |
|--------|---------|--------|------------------------------------------------------------------|

|   | • |   | reported progress of our business, relative to investor expectations; |
|--------|---------|--------|-----------------------------------------------------------------------|

|   | • |   | changes in earnings estimates, investors’ perceptions, recommendations by securities analysts or our failure to achieve analysts’ earning estimates; |
|--------|---------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | quarterly variations in our or our competitors’ results of operations; |
|--------|---------|--------|------------------------------------------------------------------------------|

|   | • |   | general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors; |
|--------|---------|--------|-------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | future sales of our common stock; |
|--------|---------|--------|-----------------------------------|

|   | • |   | announcements by us, or our competitors, of acquisitions, significant contracts, or commercial relationships; |
|--------|---------|--------|---------------------------------------------------------------------------------------------------------------|

|   | • |   | commencement of, or involvement in, litigation; |
|--------|---------|--------|-------------------------------------------------|

|   | • |   | any major change in our board of directors or management; |
|--------|---------|--------|-----------------------------------------------------------|

|   | • |   | changes in governmental regulations or in the status of our regulatory approvals; |
|--------|---------|--------|-----------------------------------------------------------------------------------|

|   | • |   | a lack of, limited, or negative industry or security analyst coverage; and |
|--------|---------|--------|----------------------------------------------------------------------------|

|   | • |   | the other factors described elsewhere in these “Risk Factors.” |
|--------|---------|--------|----------------------------------------------------------------------------|

----

significant expenses in connection with the filing of such registration statement. Additionally, the filing of an additional registration statement at the request of the stockholders may divert the attention of our senior management from our business operations.

|   | • |   | take advantage of expansion opportunities;        |
|--------|---------|--------|---------------------------------------------------|
|   |    |   |                                              |
|   | • |   | acquire complementary businesses or technologies; |
|   |    |   |                                              |
|   | • |   | develop new services and products;           |
|   | • |   | pay down or retire debt obligations; or           |
|   |    |   |                                              |

|   | • |   | respond to competitive pressures. |
|--------|---------|--------|-----------------------------------|

----

|   | • |   | our board of directors is divided into three classes serving staggered three-year terms; |
|--------|---------|--------|------------------------------------------------------------------------------------------|

|   | • |   | only our board of directors may call special meetings of our stockholders; |
|--------|---------|--------|----------------------------------------------------------------------------|

|   | • |   | our stockholders may take action only at a meeting of our stockholders and not by written consent; |
|--------|---------|--------|----------------------------------------------------------------------------------------------------|

|   | • |   | we have authorized undesignated preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval; |
|--------|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | stockholder approval of amendments of our certificate of incorporation or by-laws require a vote of 75% of our outstanding shares; |
|--------|---------|--------|------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | vacancies on the board of directors may be filled only by the directors; |
|--------|---------|--------|--------------------------------------------------------------------------|

|   | • |   | our directors may be removed only for cause by the affirmative vote of the holders of 75% of the votes that all stockholders would be entitled to cast in the election of directors; and |
|--------|---------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | we require advance notice for stockholder proposals. |
|--------|---------|--------|------------------------------------------------------|

----

| Item 1B. | Unresolved Staff Comments. |
|---------------|----------------------------|

| Item 2. | Properties. |
|--------------|-------------|

| Item 3. | Legal Proceedings. |
|--------------|--------------------|

| Item 4. | Submission of Matters to a Vote of Security Holders. |
|--------------|------------------------------------------------------|

----

PART II

| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. |
|--------------|---------------------------------------------------------------------------------------------------------------------|

|                            |   | 1/07   | 2/07   | 3/07   | 4/07   | 5/07   | 6/07   | 7/07   | 8/07   | 9/07   | 10/07  | 11/07  | 12/07  | 1/08         |
|---------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------------|
|                            |   |   |   |   |   |   |   |   |   |   |   |   |   |         |
| Animal Health International Inc | 100.00 | 103.61 | 97.11  | 107.31 | 100.00 | 116.39 | 90.44  | 91.16  | 89.40  | 87.55  | 96.39  | 98.80  | 96.39  |
| Dow Jones US                    |   | 100.00 | 98.37  | 99.45  | 103.56 | 107.42 | 105.62 | 102.18 | 103.61 | 107.48 | 109.44 | 104.66 | 104.01 | 97.74        |
| Peer Group                      |   | 100.00 | 95.60  | 102.08 | 100.36 | 103.41 | 103.03 | 103.15 | 107.66 | 111.33 | 112.49 | 103.10 | 107.95 | 102.52  |

| 2/08   | 3/08   | 4/08   | 5/08   | 6/08   | 7/08   | 8/08   | 9/08   | 10/08  | 11/08  | 12/08  | 1/09   | 2/09   | 3/09   | 4/09   | 5/09   | 6/09   |
|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| 84.66  | 87.87  | 70.60  | 54.54  | 50.04  | 44.26  | 59.92  | 66.18  | 51.81  | 11.73  | 17.11  | 12.53  | 9.88   | 10.20  | 14.30  | 12.85  | 12.45  |
| 94.74  | 94.17  | 98.96  | 100.94 | 92.75  | 91.88  | 93.27  | 84.44  | 69.64  | 64.23  | 65.36  | 60.01  | 53.83  | 58.49  | 64.55  | 68.07  | 68.25  |
| 107.89 | 106.17 | 104.22 | 105.48 | 95.68  | 99.65  | 105.70 | 100.51 | 86.62  | 68.60  | 68.14  | 68.48  | 65.69  | 69.51  | 73.04  | 76.80  | 84.06  |

----

|                                          |   | High    |   |   | Low    |    |
|-----------------------------------------------|--------|---------|--------|--------|--------|---------|
|  FISCAL 2008                             |   |    |   |   |   |    |   |   |
|  First Quarter                           |   | $       | 15.74  |   |   | $       | 8.78 |   |
|  Second Quarter                          |   | $       | 13.57  |   |   | $       | 10.02 |   |
|  Third Quarter                           |   | $       | 13.67  |   |   | $       | 9.87 |   |
|  Fourth Quarter                          |   | $       | 11.40  |   |   | $       | 5.58 |   |
|                                          |   |    |   |   |   |    |   |   |
|  FISCAL 2009                             |   |    |   |   |   |    |   |   |
|  First Quarter                           |   | $  | 8.75   |   |   | $  | 4.72 |   |
|  Second Quarter                          |   | $  | 8.55   |   |   | $       | 1.17 |   |
|  Third Quarter                           |   | $  | 2.38   |   |   | $       | 0.74 |   |
|  Fourth Quarter                          |   | $  | 2.10   |   |   | $       | 1.20 |   |
|                                          |   |    |   |   |   |    |   |   |
|  FISCAL 2010                             |   |    |   |   |   |    |   |   |
|  First Quarter (through August 31, 2009) |   | $  | 2.12   |   |   | $       |  1.19 |   |
|                                          |   |    |   |   |   |    |   |   |

----

|                                                          | Number of securities to be issued upon exercise of outstanding options, warrantsand rights |   | Weighted average exercise price of outstanding options,warrants and rights |        | Number of securities remaining available forfuture issuance under equity compensation plans (excluding securities reflectedin column (a)) |                  |
|---------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
|                                                          | (a)                                                                                        |   | (b)                                                                        |        | (c)                                                                                                                                       |                  |
| Equity compensation plans approved by security holders(1)     | 1,014,175                                                                                  |   | $                                                                          |   5.03 |                                                                                                                                      |  1,241,767       | (2) |
| Equity compensation plans not approved by security holders(3) | —                                                                                    |   |                                                                       | —     |                                                                                                                                      | —               |   |
|                                                          |                                                                                       |   |                                                                       |        |                                                                                                                                      |                  |
| Total                                                         | 1,014,175                                                                                  |   | $                                                                          |   5.03 |                                                                                                                                      |   1,241,767 |   |

| (1)       | Includes our 2007 Stock Option and Incentive Plan.                                                      |
|-----------|---------------------------------------------------------------------------------------------------------|
| (2)  | Includes shares remaining available for future issuance under our 2007 Stock Option and Incentive Plan. |
| (3)       | There are no equity compensation plans in place not approved by shareholders.                           |

| Item 6. | Selected Financial Data. |
|--------------|--------------------------|

----

|                                                                     |   | Year ended June 30, |    |
|--------------------------------------------------------------------------|--------|---------------------|---------|
| (in thousands, except per share data and number of representatives) |   |  Predecessor   |    |  Successor |   |
|                                                                     |   | 2005                |    |   |   | 2006 |   | 2007 |   |   | 2008 |   |   | 2009 |   |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |
| Net sales                                                                |   | $                   | 535,693 |   |   |   | $ | 571,192 |   | $ | 629,534 |   |   | $ | 716,542 |   |   | $ | 666,948 |   |
| Direct cost of products sold                                             |   |                | 436,955 |   |   |   |   | 459,173 |   |   | 507,997 |   |   |   | 579,485 |   |   |   | 552,994 |   |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Gross profit                                                             |   |                | 98,738  |   |   |   |   | 112,019 |   |   | 121,537 |   |   |   | 137,057 |   |   |   | 113,954 |   |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Selling, general, and                                                    |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| administrative expenses(1)                                               |   |                | 72,954  |   |   |   |   | 81,428 |   |   | 88,117 |   |   |   | 101,849 |   |   |   | 100,451 |   |
| Acquisition costs(2)                                                     |   |                | 7,759   |   |   |   |   | — |   |   | 6 |   |   |   | 37 |   |   |   | 3 |   |
| Depreciation and amortization(3)                                         |   |                | 3,149   |   |   |   |   | 6,414 |   |   | 6,504 |   |   |   | 7,349 |   |   |   | 8,223 |   |
| Goodwill impairment                                                      |   |                | — |   |   |   |   | —  |   |   |  — |   |   |   |  — |   |   |   |  25,164 |   |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Operating income (loss)                                                  |   |                | 14,876  |   |   |   |   | 24,177 |   |   | 26,910 |   |   |   | 27,822 |   |   |   | (19,887 | )  |
| Other income (expense)                                                   |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Interest expense                                                         |   |                | (5,071  | ) |   |   |   | (13,726 | )  |   | (18,307 | ) |   |   | (10,277 | ) |   |   | (8,761 | ) |
| Other income                                                             |   |                | 672     |   |   |   |   | 478 |   |   | 582 |   |   |   | 964 |   |   |   | 786 |   |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Income (loss) before income taxes                                        |   |                | 10,477  |   |   |   |   | 10,929 |   |   | 9,185 |   |   |   | 18,509 |   |   |   | (27,862 | ) |
| Income tax benefit (expense)                                             |   |                | (3,203  | ) |   |   |   | (3,542 | )  |   | (3,957 | ) |   |   | (7,408 | ) |   |   | 734 |   |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net income (loss)                                                        |   | $                   | 7,274   |   |   |   | $ | 7,387 |   | $ | 5,228 |   |   | $ | 11,101 |   |   | $ | (27,128 | )  |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Per share data:                                                          |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Earnings (loss) per common share                                         |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Basic                                                                    |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Common                                                      |   |                |    |   |   |   | $ | 0.43 |   | $ | (13.01 | )  |   |   | 0.46 |   |   |   | (1.12 | )  |
|    Class A                                                     |   | $                   | 3.38    |   |   |   | $ |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Class L                                                     |   | $                   | 3.38    |   |   |   | $ |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Class W                                                     |   | $                   | 3.38    |   |   |   | $ |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Dilutive                                                                 |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Common                                                      |   |                |    |   |   |   | $  |  0.43 |   | $ | (13.01 | )  |   |   | 0.46 |   |   |   | (1.12 | )  |
|    Class A                                                     |   | $                   | 2.82    |   |   |   | $ |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Class L                                                     |   | $                   | 2.82    |   |   |   | $ |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Class W                                                     |   | $                   | 2.82    |   |   |   | $ |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Shares used in computing earnings per share:                             |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Basic                                                                    |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Common                                                      |   |                |    |   |   |   |   | 2,084 |   |   | 11,329 |   |   |   | 24,330 |   |   |   | 24,330 |   |
|    Class A                                                     |   |                | 1,900   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Class L                                                     |   |                | 182     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Class W                                                     |   |                | 72      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted                                                                  |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Common                                                      |   |                |    |   |   |   |   | 2,084 |   |   | 11,329 |   |   |   | 24,330 |   |   |   | 24,330 |   |
|    Class A                                                     |   |                | 2,307   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Class L                                                     |   |                | 197     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Class W                                                     |   |                | 72      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated balance sheet data:                                         |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total assets                                                             |   |                | 197,449 |   |   |   |   | 294,337 |   |   | 330,034 |   |   |   | 365,299 |   |   |   | 318,265 |   |
| Total current and long-term debt                                         |   |                | 61,633  |   |   |   |   | 137,634 |   |   | 118,886 |   |   |   | 138,421 |   |   |   | 127,092 |   |
| Total stockholders' equity (deficit)                                     |   |                | 38,087  |   |   |   |   | (3,179 | )  |   | 86,115 |   |   |   | 96,224 |   |   |   | 70,381 |   |
| Cash dividend declared                                                   |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Per common share                                                         |   | $                   | — |   |   |   | $ | — |   | $ | 0.52 |   |   | $ | — |   |   | $ | — |   |
|                                                                     |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other data:                                                              |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Adjusted EBITDA(4)                                                       |   | $                   | 26,456  |   |   |   | $ | 31,069 |   | $ | 34,226 |   |   | $ | 37,514 |   |   | $ | 17,497 |   |
| Field sales representatives(5)                                           |   |                | 220     |   |   |   |   | 218 |   |   | 238 |   |   |   | 242 |   |   |   | 221 |   |

----

| (1) |   | Selling, general, and administrative expenses include (a) salary, wages, commissions, and related benefits of $39,022, $43,958, $47,619, $55,022, and $55,204 for the years ended June 30, 2005, 2006, 2007, 2008, and 2009, respectively; (b) management and advisory services fees paid to Bain Capital Partners, V, L.P. totaling$750 for the year ended June 30, 2005; (c) and management and advisory service fees and reimbursement of out-of-pocket expenses paid to Charlesbank totaling $575, $664, and $146 for the years ended June 30, 2005, 2006, and 2007, respectively. Refer to note 10 of our consolidated financial statements included in this Annual Report on Form 10-K for further information. |
|-----|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) |   | $7,759 represents costs incurred in connection with the sale of Predecessor on June 30, 2005.  $6, $37, and $3 represent costs of failed acquisitions for each of the years ended June 30, 2007, 2008, and 2009, respectively. |
|-----|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)    |   | Depreciation expense includes the depreciation of property, plant and equipment and other assets and was $3,114, $3,039, $3,129, $3,178, and $3,617 for the years ended June 30, 2005, 2006, 2007, 2008, and 2009, respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| (4)    |   | Adjusted EBITDA represents net income before interest expense, income tax expense, depreciation and amortization, goodwill impairment, stock-based compensation, and acquisition costs. We present adjusted EBITDA as a supplemental performance measure because we believe it facilitates operating performance comparisons from period to periodand company to company by backing out potential differences caused by variations in capital structures (affecting interest expense), tax positions (such as the impact on periods or companies of changes in effective tax rates or net operating losses), the age and book depreciation of fixed assets (affecting relative depreciation expense), the impact of purchase accounting and the impact of non-recurring acquisition costs. Because adjusted EBITDA facilitates internal comparisons of our historical financialposition and operating performance on a more consistent basis, we also use adjusted EBITDA in measuring our performance relative to that of our competitors and in evaluating acquisition opportunities. Adjusted EBITDA is not a measurement of our financial performance under generally accepted accounting principles in the United States (GAAP), and should not be considered as an alternative to net income, operating income or any other performance measures derived in accordance with GAAP or as an alternative to cashflow from operating activities as a measure of our profitability or liquidity. We understand that although adjusted EBITDA is frequently used by securities analysts, lenders and others in their evaluation of companies, our calculation of adjusted EBITDA may not be comparable to other similarly titled measures of other companies. EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under GAAP. Some of these limitationsare: |

|   | • |   | adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments; |
|--------|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; |
|--------|---------|--------|---------------------------------------------------------------------------------------------------|

|   | • |   | adjusted EBITDA does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on our debts; |
|--------|---------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted EBITDA does not reflect any cash requirements for such replacements; and |
|--------|---------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | other companies in our industry may calculate adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. |
|--------|---------|--------|-----------------------------------------------------------------------------------------------------------------------------------------|

|                          |   | Year ended June 30, |    |
|-------------------------------|--------|---------------------|---------|
|                          |   |  Predecessor   |    |  Successor |   |
| (in thousands)                |   | 2005                |    |   |   |  2006 |   | 2007 |   |   | 2008 |   |   | 2009 |   |
|                          |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |
| Net income (loss)             |   | $                   | 7,274   |   |   |   | $ | 7,387 |   | $ | 5,228 |   |   | $ | 11,101 |   |   | $ | (27,128 | )  |
| Interest expense              |   |                | 5,071   |   |   |   |   | 13,726 |   |   | 18,307 |   |   |   | 10,277 |   |   |   | 8,761 |   |
| Income tax expense (benefit)  |   |                | 3,203   |   |   |   |   | 3,542 |   |   | 3,957 |   |   |   | 7,408 |   |   |   | (734 | )  |
| Depreciation and amortization |   |                | 3,149   |   |   |   |   | 6,414 |   |   | 6,504 |   |   |   | 7,349 |   |   |   | 8,223 |   |
| Goodwill impairment      |   |                | — |   |   |   |   | — |   |   | —  |   |   |   | —  |   |   |   | 25,164 |   |
| Stock-based compensation      |   |                | — |   |   |   |   | — |   |   | 224 |   |   |   | 1,342 |   |   |   | 3,208 |   |
| Acquisition costs             |   |                | 7,759   |   |   |   |   | — |   |   | 6 |   |   |   | 37 |   |   |   | 3 |   |
|                          |   |                |    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Adjusted EBITDA               |   | $                   | 26,456  |   |   |   | $ | 31,069 |   | $ | 34,226 |   |   | $ | 37,514 |   |   | $ | 17,497 |   |

| (5) |   | Number of sales representatives is measured at the end of the period. Field sales representatives typically service our customers in their surrounding geographical area on a weekly basis. |
|-----|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operation. |
|--------------|---------------------------------------------------------------------------------------------|

|   | • |   | Overall growth in the dairy industry. According to the USDA over the last several years the demand for dairy products has increased. As a result, the demand for productionanimal health products in the dairy market has increased. We have capitalized on this demand with increased sales of our dairy related production animal health products. We anticipate that this trend of growth in the dairy market will continue in the future and that we will be able to fulfill the corresponding demand for related production animal health products, resulting in increased sales.  Notwithstanding the overall historicaltrend, recently, the significant supply of dairy products, combined with soft demand due to the general economic downturn has decreased the profitability of our dairy customers.  Our dairy customer's declining profitability has caused them to limit their spending on dairy related production animal health products, resulting in decreased sales. |
|--------|---------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | Consolidation by our customers in the dairy industry. The dairy market is undergoing significant consolidation resulting in a shift towards larger operations.Accordingto the USDA, dairies with 500 or more cattle currently account for 58% of the milk producing cow population in the United States, as compared to 24% in 1997.Over the last several years we have leveraged our relationships with larger dairies and our national footprint to gain market share in the dairy-related production animal healthproducts market. We anticipate that this trend of dairy consolidation will continue and we will seek to continue to gain market share. |
|--------|---------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • |   | Increased focus on companion animal customers. According to Sundale Research, over the last several years the market for companion animal health products has increased to approximately $3.5 billion. Webelieve this growth has been and will continue to be driven by the following trends: |
|--------|---------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - |   | widespread ownership of companion animals; |
|--------|---|--------|--------------------------------------------|

|   | - |   | increased importance of companion animals in households; |
|--------|---|--------|----------------------------------------------------------|

|   | - |   | growing awareness of companion animal health and wellness; |
|--------|---|--------|------------------------------------------------------------|

|   | - |   | technology migration from the human life science product sector into the practice of veterinary medicine; |
|--------|---|--------|-----------------------------------------------------------------------------------------------------------|

|   | - |   | increased marketing programs sponsored by large pharmaceutical and companion animal nutrition companies; and |
|--------|---|--------|--------------------------------------------------------------------------------------------------------------|

|   | - |   | prolonged companion animal life spans creating demand for geriatric companion animal care products. |
|--------|---|--------|-----------------------------------------------------------------------------------------------------|

----

|         |    |   |     Over the past three years, we have begun to penetrate the urban and suburban veterinarian markets. We believe that by leveraging our centralized procurement and inventory management model we are well positioned to develop a leading cost-to-serve position in the companion animal health products market and to continue tocapture market share, resulting in increased sales and profitability. While we believe we are a leader in the companion animal health product market, the market is highly fragmented with numerous national, regional and local distributors, and a few of our competitors with bigger market share have greater financial and other resources than we do. |
|--------------|---------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |    |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|    | • |   | Changes in consumer preferences. The demand for production animal health products is heavily dependent upon consumer demand for beef, dairy, poultry and swine. The food industry in general is subject to changing consumer trends, demands and preferences. For example, changes in consumerdiets may negatively affect consumer demand for beef, dairy, poultry or swine, and therefore reduce the demand for our production animal health products. During the previous downturns in these markets, we experienced declines in sales.                                                                                                                                                                           |

----

|                                                                                                          |   | Year ended June 30, |    |
|---------------------------------------------------------------------------------------------------------------|--------|---------------------|---------|
| (dollars in thousands)                                                                                        |   | 2007                |    |   | 2008 |   |   | 2009 |   |
|                                                                                                          |   |                |    |   |   |   |   |   |   |
| Net sales                                                                                                     |   | $                   | 629,534 |   |   | $ | 716,542 |   |   | $ | 666,948 |   |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Direct cost of products sold                                                                                  |   |                | 507,997 |   |   |   | 579,485 |   |   |   | 552,994 |   |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Gross profit                                                                                                  |   |                | 121,537 |   |   |   | 137,057 |   |   |   | 113,954 |   |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Selling, general, and administrative expenses (includes salary, wages, commission, and related benefits)      |   |                | 88,117  |   |   |   | 101,849 |   |   |   | 100,451 |   |
| Acquisition costs                                                                                             |   |                | 6       |   |   |   | 37 |   |   |   | 3 |   |
| Depreciation and amortization                                                                                 |   |                | 6,504   |   |   |   | 7,349 |   |   |   | 8,223 |   |
| Goodwill impairment                                                                                 |   |                | — |   |   |   | — |   |   |   | 25,164 |   |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Operating income (loss)                                                                                       |   |                | 26,910  |   |   |   | 27,822 |   |   |   | (19,887 | )  |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Other income (expense):                                                                                       |   |                |    |   |   |   |   |   |   |   |   |   |
| Interest expense                                                                                              |   |                | (18,307 | ) |   |   | (10,277 | ) |   |   | (8,761 | ) |
| Other income                                                                                                  |   |                | 582     |   |   |   | 964 |   |   |   | 786 |   |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Income (loss) before income taxes                                                                        |   |                | 9,185   |   |   |   | 18,509 |   |   |   | (27,862 | )  |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Income tax benefit (expense)                                                                                  |   |                | (3,957  | ) |   |   | (7,408 | ) |   |   | 734 |   |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Net income (loss)                                                                                             |   | $                   | 5,228   |   |   | $ | 11,101 |   |   | $ | (27,128 | )  |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Net sales                                                                                                     |   |                | 100.0   | % |   |   | 100.0 | % |   |   | 100.0 | % |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Direct cost of products sold                                                                                  |   |                | 80.7    | % |   |   | 80.9 | % |   |   | 82.9 | % |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Gross profit                                                                                                  |   |                | 19.3    | % |   |   | 19.1 | % |   |   | 17.1 | % |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Selling, general, and administrative expenses (includes salary, wages, commission, and related benefits) |   |                | 14.0    | % |   |   | 14.2 | % |   |   | 15.1 | % |
| Acquisition costs                                                                                             |   |                | 0.0     | % |   |   | 0.0 | % |   |   | 0.0 | % |
| Depreciation and amortization                                                                                 |   |                | 1.0     | % |   |   | 1.0 | % |   |   | 1.2 | % |
| Goodwill impairment                                                                                      |   |                | — |   |   |   | — |   |   |   | 3.8 | % |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Operating income (loss)                                                                                       |   |                | 4.3     | % |   |   | 3.9 | % |   |   | -3.0 | % |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Other income (expense):                                                                                       |   |                |    |   |   |   |   |   |   |   |   |   |
| Interest expense                                                                                              |   |                | -2.9    | % |   |   | -1.4 | % |   |   | -1.3 | % |
| Other income                                                                                                  |   |                | 0.1     | % |   |   | 0.1 | % |   |   | 0.1 | % |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Income (loss) before income taxes                                                                        |   |                | 1.5     | % |   |   | 2.6 | % |   |   | -4.2 | % |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Income tax benefit (expense)                                                                                  |   |                | -0.7    | % |   |   | -1.0 | % |   |   | 0.1 | % |
|                                                                                                          |   |                |    |   |   |   |   |   |   |   |   |   |
| Net income (loss)                                                                                             |   |                | 0.8     | % |   |   | 1.6 | % |   |   | -4.1 | % |

----

----

----

|                                                 |   | September 30, |    |   | December 31, |   |    | March 31, |   |   | June 30, |   |   | September 30, |    |   | December 31, |   |    | March 31, |   |   | June 30, |   |
|------------------------------------------------------|--------|---------------|---------|--------|--------------|--------|---------|-----------|--------|--------|----------|--------|--------|---------------|---------|--------|--------------|--------|---------|-----------|--------|--------|----------|--------|
| (in thousands)                                       |   | 2007          |    |   | 2007         |   |    | 2008      |   |   | 2008     |   |   | 2008          |    |   | 2008         |   |    | 2009      |   |   | 2009     |   |
|                                                 |   |          |    |   |         |   |    |      |   |   |     |   |   |          |    |   |         |   |    |      |   |   |     |   |
| Net sales                                            |   | $             | 164,365 |   |         | $      | 203,230 |      |   | $      | 170,650  |   |   | $             | 178,297 |   |         | $      | 169,023 |      |   | $      | 184,477  |   |   | $ | 150,931 |   |   | $ | 162,517 |   |
| Direct cost of products sold                         |   |          | 135,734 |   |         |   | 163,326 |      |   |   | 137,815  |   |   |          | 142,610 |   |         |   | 138,723 |      |   |   | 152,209  |   |   |   | 125,602 |   |   |   | 136,460 |   |
|                                                 |   |          |    |   |         |   |    |      |   |   |     |   |   |          |    |   |         |   |    |      |   |   |     |   |   |   |   |   |   |   |   |   |
| Gross profit                                         |   |          | 28,631  |   |         |   | 39,904  |      |   |   | 32,835   |   |   |          | 35,687  |   |         |   | 30,300  |      |   |   | 32,268   |   |   |   | 25,329 |   |   |   | 26,057 |   |
| Selling, general, and                                |   |          |    |   |         |   |    |      |   |   |     |   |   |          |    |   |         |   |    |      |   |   |     |   |   |   |   |   |   |   |   |   |
| administrative expenses(1)                           |   |          | 22,917  |   |         |   | 26,262  |      |   |   | 25,546   |   |   |          | 27,124  |   |         |   | 25,618  |      |   |   | 24,397   |   |   |   | 22,227 |   |   |   | 28,209 |   |
| Acquisition costs                                    |   |          | — |   |         |   | — |      |   |   | —  |   |   |          | 37      |   |         |   | — |      |   |   | —  |   |   |   | — |   |   |   | 3 |   |
| Depreciation and     amortization     |   |          | 1,645   |   |         |   | 1,712   |      |   |   | 1,924    |   |   |          | 2,068   |   |         |   | 2,076   |      |   |   | 2,054    |   |   |   | 2,039 |   |   |   | 2,054 |   |
| Goodwill impairment                             |   |          | — |   |         |   | — |      |   |   | —  |   |   |          | — |   |         |   | — |      |   |   | —  |   |   |   | — |   |   |   | 25,164 |   |
|                                                 |   |          |    |   |         |   |    |      |   |   |     |   |   |          |    |   |         |   |    |      |   |   |     |   |   |   |   |   |   |   |   |   |
| Operating income (loss)                              |   |          | 4,069   |   |         |   | 11,930  |      |   |   | 5,365    |   |   |          | 6,458   |   |         |   | 2,606   |      |   |   | 5,817    |   |   |   | 1,063 |   |   |   | (29,373 | )  |
| Other income (expense):                              |   |          |    |   |         |   |    |      |   |   |     |   |   |          |    |   |         |   |    |      |   |   |     |   |   |   |   |   |   |   |   |   |
|    Other income                            |   |          | 287     |   |         |   | 266     |      |   |   | 219      |   |   |          | 192     |   |         |   | 229     |      |   |   | 189      |   |   |   | 206 |   |   |   | 162 |   |
|    Interest expense                        |   |          | (2,647  | )      |         |   | (2,719  | )         |   |   | (2,492   | )      |   |          | (2,419  | )      |         |   | (2,334  | )         |   |   | (2,289   | )      |   |   | (1,877 | ) |   |   | (2,261 | ) |
|                                                 |   |          |    |   |         |   |    |      |   |   |     |   |   |          |    |   |         |   |    |      |   |   |     |   |   |   |   |   |   |   |   |   |
| Income (loss) before income     taxes |   |          | 1,709   |   |         |   | 9,477   |      |   |   | 3,092    |   |   |          | 4,231   |   |         |   | 501     |      |   |   | 3,717    |   |   |   | (608 | )  |   |   | (31,472 | )  |
| Income tax benefit (expense)                         |   |          | (688    | )      |         |   | (3,930  | )         |   |   | (1,215   | )      |   |          | (1,575  | )      |         | (217   | )       |      |   | (1,448 | )        |   |   | 284 |   |   |   | 2,115 |   |
|                                                 |   |          |    |   |         |   |    |      |   |   |     |   |   |          |    |   |         |   |    |      |   |   |     |   |   |   |   |   |   |   |   |   |
| Net income (loss)                                    |   | $             | 1,021   |   |         | $      | 5,547   |      |   | $      | 1,877    |   |   | $             | 2,656   |   |         | $      | 284     |      |   | $      | 2,269    |   |   | $ | (324 | )  |   | $ | (29,357 | )  |

| (1) | Includes salaries, wages, commissions, and related benefits. |
|-----|--------------------------------------------------------------|

----

from thepay off of the second lien notes. The change in working capital included an increase in inventories of $5.9 million and changes in income tax receivables/payables of $3.4 million, partially offset by an increase in accounts payable of $8.2 million. The increase in inventories resulted from a rise in inventory purchases that drove the corresponding increase in accounts payable. The change in income tax receivables/payables resulted from estimated tax payments partially offset by income tax accruals.

----

----

|                                                                                                 |   |   |    |   |  Payments Due by Period |   |
|------------------------------------------------------------------------------------------------------|--------|--------|---------|--------|---------------------------------------------|--------|
| (in thousands)                                                                                       |   | Total  |    |   | 1 Year orLess                               |   |   | More than 1 Year-3 Years |   |   | More than 3 Year-5 Years |   |   | More than5 Years |   |
| Revolver                                                                                             |   | $      | 79,245  |   |                                        | $      | — |   |   | $ | 79,245 |   |   | $ | — |   |   | $ | — |   |
| Operating lease commitments                                                                          |   |   | 18,640  |   |                                        |   | 4,646 |   |   |   | 7,358 |   |   |   | 4,506 |   |   |   | 2,130 |   |
| Long-term debt and interest rate swap    obligations (including current portion) |   |   | 47,847  |   |                                        |   | 7,179 |   |   |   | 40,668 |   |   |   | — |   |   |   | — |   |
| Interest on long-term debt and line-of-credit(1)                                                     |   |   | 9,006   |   |                                        |   | 5,766 |   |   |   | 3,240 |   |   |   | — |   |   |   | — |   |
| Total contractual obligations(2)                                                                     |   | $      | 154,738 |   |                                        | $      | 17,591 |   |   | $ | 130,511 |   |   | $ | 4,506 |   |   | $ | 2,130 |   |

| (1) | Future interest payments are calculated based on the assumption that all debt is outstanding until maturity. For debt instruments with variable interest rates, interest has been calculated for all future periods using the rates in effect as of June 30, 2009. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | The Company is subject to purchase obligations under certain of its purchase contracts, but management does not believe that they are material. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk. |
|---------------|-------------------------------------------------------------|

| Item 8. | Financial Statements and Supplementary Data. |
|--------------|----------------------------------------------|

| Item 9. | Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. |
|--------------|---------------------------------------------------------------------------------------|

| Item 9A. | Controls and Procedures. |
|---------------|--------------------------|

----

| Item 9B. | Other Information. |
|---------------|--------------------|

----

PART III

| Item 10. | Directors, Executive Officers and Corporate Governance. |
|---------------|---------------------------------------------------------|

| Item 11. | Executive Compensation. |
|---------------|-------------------------|

| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. |
|---------------|-------------------------------------------------------------------------------------------------|

| Item 13. | Certain Relationships and Related Transactions, and Director Independence. |
|---------------|----------------------------------------------------------------------------|

| Item 14. | Principal Accounting Fees and Services. |
|---------------|-----------------------------------------|

----

PART IV

| Item 15. | Exhibits and Financial Statement Schedules. |
|---------------|--------------------------------------------------|

| (1) | Financial Statements: Reference is made to the Index to Financial Statements in the section entitled “Financial Statements and Supplementary Data” in Part II, Item 8 of this Annual Report on Form 10-K. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Financial Statement Schedules: These Schedules have been omitted because they are not required or because the required information is given in the consolidated financial statements or notes thereto. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Exhibits: Exhibits are as set forth in the section entitled “Exhibit Index” which follows the section entitled “Signatures” in this Annual Report on Form 10-K. Exhibits which are incorporated herein by reference can be inspected and copied at the public referencerooms maintained by the SEC in Washington, D.C., New York, New York, and Chicago, Illinois. Please call the SEC at 1-800-SEC-0330 for further information on the public reference rooms. SEC filings are also available to the public from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

SIGNATURES

|                    |         |                                                                                          |
|-------------------------|--------------|-----------------------------------------------------------------------------------------------|
|                    |    | ANIMAL HEALTH INTERNATIONAL, INC.                                                             |
|                    |         |
| Date: September 3, 2009 |    | /s/    WILLIAM F. LACEY           |
|                    |    | William F. Lacey                                                                              |
|                    |    | Senior Vice President and Chief Financial Officer(Principal Financial and Accounting Officer) |

----

|                                                                                                        |         |                                                                                                             |   |              |
|-------------------------------------------------------------------------------------------------------------|--------------|------------------------------------------------------------------------------------------------------------------|--------|-------------------|
| Signature                                                                                              |    | Title                                                                                                       |   | Date         |
|                                                                                                        |         |                                                                                                             |
| /s/    JAMES C. ROBISON        James C. Robison |    | Chief Executive Officer, President and Chairman  (Principal Executive Officer)                    |   | September 3, 2009 |
|                                                                                                        |         |                                                                                                             |
| /s/    WILLIAM F. LACEY        William F. Lacey |    | Sr. Vice President and Chief Financial Officer  (Principal Financial and Accounting Officer) |   | September 3, 2009 |
|                                                                                                        |         |                                                                                                             |
| /s/    MICHAEL EISENSON        Michael Eisenson |    | Director                                                                                                         |   | September 3, 2009 |
|                                                                                                        |         |                                                                                                             |
| /s/    MARK ROSEN        Mark Rosen             |    | Director                                                                                                         |   | September 3, 2009 |
|                                                                                                        |         |                                                                                                             |
| /s/    BRANDON WHITE        Brandon White       |    | Director                                                                                                         |   | September 3, 2009 |
|                                                                                                        |         |                                                                                                             |
| /s/    RONALD STEINHART        Ronald Steinhart |    | Director                                                                                                         |   | September 3, 2009 |
|                                                                                                        |         |                                                                                                             |
| /s/    DAVID BIEGLER        David Biegler       |    | Director                                                                                                         |   | September 3, 2009 |
|                                                                                                        |         |                                                                                                             |
| /s/    JERRY PINKERTON        Jerry Pinkerton   |    | Director                                                                                                         |   | September 3, 2009 |
|                                                                                                        |         |                                                                                                             |   |              |
| /s/    E. THOMAS CORCORAN    E. Thomas Corcoran                     |    | Director                                                                                                         |   | September 3, 2009 |

----

Index to consolidated financial statements

|                                                                                                                                             |         |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Management's Annual Report on Internal Control over Financial Reporting                                                                          |         |  F-2 |
|                                                                                                                                             |         |   |
| Reports of Independent Registered Public Accounting Firms                                                                                        |         | F-3 |
|                                                                                                                                             |         |   |
| Consolidated Balance Sheets as of June 30, 2008 and 2009                                                                                    |         | F-5 |
|                                                                                                                                             |         |
| Consolidated Statements of Operations for the years ended June 30, 2007, 2008 and 2009                                                      |         | F-6 |
|                                                                                                                                             |         |
| Consolidated Statements of Stockholders’ Equity and Comprehensive Income (Loss) for the years ended June 30, 2007, 2008 and 2009 |         | F-7 |
|                                                                                                                                             |         |
| Consolidated Statements of Cash Flows for the years ended June 30, 2007, 2008 and 2009                                                      |         | F-8 |
|                                                                                                                                             |         |
| Notes to Consolidated Financial Statements                                                                                                       |    | F-9 |

----

Management's Annual Report on Internal Control Over Financial Reporting

|   |   | /s/ James C. RobisonJames C. RobisonChief Executive Officer of the Company       |
|--------|--------|----------------------------------------------------------------------------------|
|   |   |  /s/ William F. LaceyWilliam F. LaceyChief Financial Officer of the Company |

----

  

----

|   | /s/ KPMG LLP |
|--------|--------------|

----

ANIMAL HEALTH INTERNATIONAL, INC.

Consolidated Balance Sheets

|                                                                      |   | June 30, 2008 |    |          | June 30, 2009 |   |
|---------------------------------------------------------------------------|--------|--------------------|---------|---------------|--------------------|--------|
| Assets                                                                    |   |               |    |          |               |   |
| Current assets:                                                           |   |               |    |          |               |   |
| Cash and cash equivalents                                                 |   | $                  | 2,452   |          |               | $      | 2,749 |   |
| Accounts receivable, net                                                  |   |               | 84,549  |          |               |   | 74,441 |   |
| Current portion of notes receivable                                       |   |               | 608     |          |               |   | 126 |   |
| Income tax receivable                                                     |   |               | 1,167   |          |               |   | 1,001 |   |
| Merchandise inventories, net                                              |   |               | 98,847  |          |               |   | 89,315 |   |
| Deferred income taxes                                                     |   |               | 2,682   |          |               |   | 3,358 |   |
| Prepaid expenses                                                          |   |               | 1,657   |          |               |   | 2,319 |   |
| Total current assets                                                      |   |               | 191,962 |          |               |   | 173,309 |   |
| Noncurrent assets:                                                        |   |               |    |          |               |   |   |   |
| Notes receivable, net of current portion                                  |   |               | 511     |          |               |   | 280 |   |
| Property, plant, and equipment, net                                       |   |               | 17,096  |          |               |   | 16,043 |   |
| Goodwill                                                             |   |               | 82,642  |          |               |   | 60,334 |   |
| Customer relationships, net                                               |   |               | 31,428  |          |               |   | 28,022 |   |
| Noncompete agreements, net                                                |   |               | 4,636   |          |               |   | 3,436 |   |
| Trademarks and trade names                                                |   |               | 33,170  |          |               |   | 33,170 |   |
| Debt issue costs and other assets, net                                    |   |               | 3,854   |          |               |   | 3,671 |   |
| Total assets                                                              |   | $                  | 365,299 |          |               | $      | 318,265 |   |
|                                                                      |   |               |    |          |               |   |   |   |
| Liabilities and Stockholders’ Equity                                |   |               |    |          |               |   |   |   |
| Current liabilities:                                                      |   |               |    |          |               |   |   |   |
| Accounts payable                                                          |   | $                  | 86,213  |          |               | $      | 83,567 |   |
| Accrued liabilities                                                       |   |               | 13,879  |          |               |   | 13,055 |   |
| Current portion of long-term debt                                         |   |               | 1,259   |          |               |   | 7,179 |   |
| Total current liabilities                                                 |   |               | 101,351 |          |               |   | 103,801 |   |
|                                                                      |   |               |    |          |               |   |   |   |
| Noncurrent liabilities:                                                   |   |               |    |          |               |   |   |   |
| Long-term debt, net of current portion                                    |   |               | 137,162 |          |               |   | 119,913 |   |
| Deferred lease incentives                                                 |   |               | 1,437   |          |               |   | 1,101 |   |
| Deferred income taxes                                                     |   |               | 26,282  |          |               |   | 23,069 |   |
| Other long-term liabilities                                               |   |               | 2,843   |          |               |   | — |   |
| Total liabilities                                                         |   |               | 269,075 |          |               |   | 247,884 |   |
|                                                                      |   |               |    |          |               |   |   |   |
| Commitments and contingencies (note 14)                                   |   |               |    |          |               |   |   |   |
| Stockholders’ equity:                                               |   |               |    |          |               |   |   |   |
| Preferred stock, par value $0.01 per share. Authorized 10,000,000 shares, |   |               |    |          |               |   |   |   |
| issued and outstanding 0 shares                                           |   |               | — |          |               |   | — |   |
| Common stock, par value $0.01 per share. Authorized 90,000,000 shares,    |   |               |    |          |               |   |   |   |
| issued and outstanding 24,329,670 shares                                  |   |               | 243     |          |               |   | 243 |   |
| Additional paid-in capital                                                |   |               | 129,704 |          |               |   | 132,912 |   |
| Accumulated deficit                                                       |   |               | (31,725 | )   |               |   | (58,853 | )   |
| Accumulated other comprehensive loss                                      |   |               | (1,998  | )        |               |   | (3,921 | )   |
| Total stockholders’ equity                                          |   |               | 96,224  |          |               |   | 70,381 |   |
|                                                                      |   |               |    |          |               |   |   |   |
| Total liabilities and stockholders’ equity                          |   | $                  | 365,299 |          |               | $      | 318,265 |   |

----

ANIMAL HEALTH INTERNATIONAL, INC.

Consolidated Statements of Operations

|                                                                  |   | Year ended June 30, |     |
|-----------------------------------------------------------------------|--------|---------------------|----------|
|                                                                  |   | 2007                |     |   | 2008 |   |   | 2009 |   |
| Net sales                                                             |   | $                   | 629,534  |   |   | $ | 716,542 |   |   | $ | 666,948 |   |
| Costs and expenses:                                                   |   |                |     |   |   |   |   |   |   |   |   |   |
| Direct cost of products sold (excludes depreciation and amortization) |   |                | 507,997  |   |   |   | 579,485 |   |   |   | 552,994 |   |
| Salaries, wages, commissions, and related benefits                    |   |                | 47,619   |   |   |   | 55,022 |   |   |   | 55,204 |   |
| Selling, general, and administrative                                  |   |                | 40,498   |   |   |   | 46,827 |   |   |   | 45,247 |   |
| Acquisition costs                                                     |   |                | 6        |   |   |   | 37 |   |   |   | 3 |   |
| Depreciation and amortization                                         |   |                | 6,504    |   |   |   | 7,349 |   |   |   | 8,223 |   |
| Goodwill impairment                                              |   |                | —  |   |   |   | — |   |   |   | 25,164 |   |
| Operating income (loss)                                               |   |                | 26,910   |   |   |   | 27,822 |   |   |   | (19,887 | ) |
| Other income (expense):                                               |   |                |     |   |   |   |   |   |   |   |   |   |
| Other income                                                          |   |                | 582      |   |   |   | 964 |   |   |   | 786 |   |
| Interest expense                                                      |   |                | (18,307  | )   |   |   | (10,277 | )   |   |   | (8,761 | )   |
| Income (loss) before income taxes                                     |   |                | 9,185    |   |   |   | 18,509 |   |   |   | (27,862 | )  |
|                                                                  |   |                |     |   |   |   |   |   |   |   |   |   |
| Income tax beneift (expense)                                          |   |                | (3,957   | )   |   |   | (7,408 | )   |   |   | 734 |    |
| Net income (loss)                                                     |   | $                   | 5,228    |   |   | $ | 11,101 |   |   | $ | (27,128 | )  |
| Dividend on redeemable preferred stock                                |   |                | (53,323  | )   |   |   | — |    |   |   | — |   |
| Deemed dividend upon conversion of redeemable preferred stock         |   |                | (95,227  | )  |   |   | — |    |   |   | — |   |
| Preferred stock participation in undistributed earnings               |   |                | (4,062   | )   |   |   | — |    |   |   | — |   |
| Net income (loss) available to common shareholders                    |   | $                   | (147,384 | )  |   | $ | 11,101 |   |   | $ | (27,128 | )  |
| Earnings (loss) per common share:                                     |   |                |     |   |   |   |   |   |   |   |   |   |
| Basic                                                                 |   | $                   | (13.01   | )  |   | $ | 0.46 |   |   | $ | (1.12 | )  |
| Diluted                                                               |   | $                   | (13.01   | )  |   | $ | 0.46 |   |   | $ | (1.12 | )  |
| Shares used in computing earnings per share:                          |   |                |     |   |   |   |   |   |   |   |   |   |
| Basic                                                                 |   |                | 11,329   |   |   |   | 24,330 |   |   |   | 24,330 |   |
| Diluted                                                               |   |                | 11,329   |   |   |   | 24,330 |   |   |   | 24,330 |   |
|                                                                  |   |                |     |   |   |   |   |   |   |   |   |   |
| See accompanying Notes to Consolidated Financial Statements.          |

----

ANIMAL HEALTH INTERNATIONAL, INC.

onsolidated Statements of Stockholders’ Equity and Comprehensive Income

|                                                                                                                                                         |   | Common stock |          |          |   |    |          |       |   |    | Accumulated   |          |   |          |          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|---------------|---------------|--------|---------|---------------|------------|--------|---------|---------------|---------------|--------|---------------|---------------|
|                                                                                                                                                         |   |         |          |          |   |    |          | Additional |   |    | Accumulated   |          |   | other         |          |   |   |   |
|                                                                                                                                                         |   | Number of    |          |          |   |    |          | paid-in    |   |    | earnings/     |          |   | comprehensive |          |   |   |   |
|                                                                                                                                                         |   | shares       |          |          | Amount |    |          | capital    |   |    | (deficit)     |          |   | income (loss) |          |   | Total |   |
| Balance, June 30, 2006                                                                                                                                       |   |         | 2,259,991     |          |   | $       | 23            |       |   | $       | (9,405        | )             |   | $             | 6,446         |   |   | $ | (243 | )   |   | $ | (3,179 | ) |
| Dividend on common stock  of $0.52 per share                                                                                                            |   |         | —       |          |   |    | —       |       |   |    | —       |          |   |          | (1,177        | )   |   |   | — |   |   |   | (1,177 | )   |
| Dividend on redeemable preferred  stock of $25.12 per share                                                                                             |   |         | —       |          |   |    | —       |       |   |    | —       |          |   |          | (53,323       | )   |   |   | — |   |   |   | (53,323 | )   |
| Forfeiture of common stock                                                                                                                                   |   |         | (5,503        | )   |   |    | (1            | )          |   |    | —       |          |   |          | —       |   |   |   | — |   |   |   | (1 | )   |
| Conversion of redeemable preferred  stock into common stock                                                                                             |   |         | 12,975,182    |          |   |    | 13            | 0     |   |    | 47,370        |          |   |          | —       |   |   |   | — |   |   |   | 47,500 |   |
| Sale of common stock under initial public offering                                                                                                           |   |         | 9,100,000     |          |   |    | 91            |       |   |    | 102,088       |          |   |          | —       |   |   |   | — |   |   |   | 102,179 |   |
| Costs directly associated with initial public offering                                                                                                       |   |         | —       |          |   |    | —       |       |   |    | (11,910       | )   |   |          | —       |   |   |   | — |   |   |   | (11,910 | )   |
| Stock-based compensation                                                                                                                                     |   |         | —       |          |   |    | —       |       |   |    | 224           |          |   |          | —       |   |   |   | — |   |   |   | 224 |   |
| Comprehensive income:                                                                                                                                        |   |         |          |          |   |    |          |       |   |    |          |          |   |          |          |   |   |   |   |   |   |   |   |   |
| Net income                                                                                                                                                   |   |         | —       |          |   |    | —       |       |   |    | —       |          |   |          | 5,228         |   |   |   | — |   |   |   | 5,228 |   |
| Unrealized gain on derivative  instruments, net of tax                                                                                                  |   |         | —       |          |   |    | —       |       |   |    | —  |          |   |          | —  |   |   |   | 535 |   |   |   | 535 |   |
| Foreign currency translation  adjustment                                                                                                                |   |         | —       |          |   |    | —  |       |   |    | —  |          |   |          | —  |   |   |   | 39 |   |   |   | 39 |   |
| Total comprehensive income                                                                                                                                   |   |         |          |          |   |    |          |       |   |    |          |          |   |          |          |   |   |   |   |   |   |   | 5,802 |   |
| Balance, June 30, 2007                                                                                                                                       |   |         | 24,329,670    |          |   | $       | 243           |       |   | $       | 128,367       |          |   | $             | (42,826       | )   |   | $ | 331 |   |   | $ | 86,115 |   |
| Costs directly associated with initial   public offering                                                                                                |   |         | —       |          |   |    | —       |       |   |    | (5            | )   |   |          | —       |   |   |   | — |   |   |   | (5 | )   |
| Stock-based compensation                                                                                                                                     |   |         | —       |          |   |    | —       |       |   |    | 1,342         |          |   |          | —       |   |   |   | — |   |   |   | 1,342 |   |
| Comprehensive income:                                                                                                                                        |   |         |          |          |   |    |          |       |   |    |          |          |   |          |          |   |   |   |   |   |   |   |   |   |
| Net income                                                                                                                                                   |   |         | —       |          |   |    | —       |       |   |    | —       |          |   |          | 11,101        |   |   |   | — |   |   |   | 11,101 |   |
| Unrealized loss on derivative   instruments, net of tax                                                                                                 |   |         | —  |          |   |    | —  |       |   |    | —  |          |   |          | —  |   |   |   | (2,241 | )  |   |   | (2,241 | ) |
| Foreign currency translation  adjustment                                                                                                                |   |         | —  |          |   |    | —  |       |   |    | —  |          |   |          | —  |   |   |   | (88 | ) |   |   | (88 | )  |
| Total comprehensive income                                                                                                                                   |   |         |          |          |   |    |          |       |   |    |          |          |   |          |          |   |   |   |   |   |   |   | 8,772 |   |
| Balance, June 30, 2008                                                                                                                                       |   |         | 24,329,670    |          |   | $       | 243           |       |   | $       | 129,704       |          |   | $             | (31,725       | )   |   | $ | (1,998 | )   |   | $ | 96,224 |   |
| Stock-based compensation                                                                                                                                     |   |         | —  |          |   |    | —  |       |   |    | 1,405         |          |   |          | —  |   |   |   | —  |   |   |   | 1,405 |   |
| Voluntary cancellation of stock     options                                                                                              |   |         | —  |          |   |    | —  |       |   |    | 1,803         |          |   |          | —  |   |   |   | —  |   |   |   | 1,803 |   |
|  Comprehensive income:                                                                                                                                  |   |         |          |          |   |    |          |       |   |    |          |          |   |          |          |   |   |   |   |   |   |   |   |   |
|        Net loss                                                                                                           |   |         | —  |          |   |    | —  |       |   |    | —  |          |   |          | (27,128       | )  |   |   | —  |   |   |   | (27,128 | ) |
|        Unrealized loss on derivative            instruments, net of tax |   |         | —  |          |   |    | —  |       |   |    | —  |          |   |          | —  |   |   |   | (646 | )  |   |   | (646 | )  |
|        Foreign currency translation           adjustment                          |   |         | —  |          |   |    | —  |       |   |    | —  |          |   |          | —  |   |   |   | (1,277 | )  |   |   | (1,277 | )  |
|  Total comprehensive loss                                                                                                                               |   |         |          |          |   |    |          |       |   |    |          |          |   |          |          |   |   |   |   |   |   |   | (29,051 | )  |
|  Balance, June 30, 2009                                                                                                                                 |   |         | 24,329,670    |          |   | $  | 243           |       |   |  $ | 132,912       |          |   | $             | (58,853       | )  |   | $ | (3,921 | )  |   |  $ | 70,381 |   |
|                                                                                                                                                         |   |         |          |          |   |    |          |       |   |    |          |          |   |          |          |   |   |   |   |   |   |   |   |   |
| See accompanying Notes to Consolidated Financial Statements.                                                                                                 |   |

----

ANIMAL HEALTH INTERNATIONAL, INC.

Consolidated Statements of Cash Flows

|                                                                |   | Year ended June 30, |     |
|---------------------------------------------------------------------|--------|---------------------|----------|
|                                                                |   | 2007                |     |   | 2008 |   |   | 2009 |   |
| Cash flows from operating activities:                               |   |                |     |   |   |   |   |   |   |
| Net income (loss)                                                   |   | $                   | 5,228    |   |   | $ | 11,101 |   |   | $ | (27,128 | )  |
| Adjustments to reconcile net income (loss) to net                   |   |                |     |   |   |   |   |   |   |   |   |   |
|   cash provided by operating activities:                  |   |                |     |   |   |   |   |   |   |   |   |   |
| Depreciation and amortization                                       |   |                | 6,504    |   |   |   | 7,349 |   |   |   | 8,223 |   |
| Goodwill impairment                                            |   |                | —  |   |   |   | — |   |   |   | 25,164 |   |
| Amortization of debt issue costs                                    |   |                | 2,214    |   |   |   | 805 |   |   |   | 728 |   |
| Bad debt expense (recovery)                                         |   |                | (293     | )  |   |   | 690 |   |   |   | 3,184 |   |
| Stock-based compensation                                            |   |                | 224      |   |   |   | 1,342 |   |   |   | 3,208 |   |
| Gain on sale of equipment                                           |   |                | (26      | )  |   |   | (292 | )   |   |   | (219 | )   |
| Deferred income taxes                                               |   |                | (2,629   | )   |   |   | 1,167 |    |   |   | (3,228 | )  |
| Deferred lease incentives                                           |   |                | —  |   |   |   | 224 |    |   |   | — |   |
| Changes in assets and liabilities (net of effects of acquisitions): |   |                |     |   |   |   |   |   |   |   |   |   |
|   Accounts receivable                                     |   |                | 1,656    |   |   |   | (1,792 | )  |   |   | 5,986 |    |
|   Merchandise inventories                                 |   |                | (5,935   | )   |   |   | 1,634 |    |   |   | 8,365 |   |
|   Income taxes receivable/payable                         |   |                | (3,353   | )  |   |   | 12 |    |   |   | 368 |   |
|   Prepaid expenses                                        |   |                | (509     | )   |   |   | 948 |    |   |   | (679 | )  |
|   Accounts payable                                        |   |                | 8,171    |    |   |   | (7,348 | )  |   |   | (2,931 | )   |
|   Accrued liabilities and other                           |   |                | (822     | )  |   |   | (9,877 | )   |   |   | 756 |    |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| Net cash provided by operating activities                           |   |                | 10,430   |   |   |   | 5,963 |   |   |   | 21,797 |   |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| Cash flows from investing activities:                               |   |                |     |   |   |   |   |   |   |   |   |   |
| Purchase of property, plant, and equipment                          |   |                | (3,567   | )   |   |   | (4,074 | )   |   |   | (2,856 | )   |
| Disposition (purchase) of other assets                              |   |                | (395     | )   |   |   | (12 | )   |   |   | 289 |    |
| Business acquisitions, net of cash acquired (includes $1,376 and    |   |                |     |   |   |   |   |   |   |   |   |   |
|   $1,017 of direct acquisition costs)                     |   |                | (21,936  | )  |   |   | (23,033 | )   |   |   | — |    |
| Purchase price adjustments                                          |   |                | 742      |   |   |   | (2,246 | )  |   |   | (2,856 | )   |
| Proceeds from sale of property, plant, and equipment                |   |                | 206      |   |   |   | 1,674 |   |   |   | 509 |   |
| Net changes in notes receivable                                     |   |                | 275      |   |   |   | 144 |   |   |   | 700 |   |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| Net cash used for investing activities                              |   |                | (24,675  | )   |   |   | (27,547 | )   |   |   | (4,214 | )   |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| Cash flows from financing activities:                               |   |                |     |   |   |   |   |   |   |   |   |   |
| Repayment of long-term debt                                         |   |                | (112,381 | )   |   |   | (45,933 | )   |   |   | (1,270 | )   |
| Borrowings of long-term debt                                        |   |                | 90,002   |   |   |   | 44,550 |   |   |   | — |   |
| Net borrowings (repayments) under revolving credit facilities       |   |                | 1,188    |    |   |   | 20,902 |   |   |   | (15,211 | )  |
| Debt issue costs                                                    |   |                | (630     | )   |   |   | (487 | )   |   |   | (1,098 | )   |
| Change in overdraft balances                                        |   |                | 4,833    |    |   |   | (2,937 | )  |   |   | 333 |    |
| Dividend on redeemable preferred stock                              |   |                | (53,323  | )   |   |   | — |    |   |   | — |   |
| Dividend on common stock                                            |   |                | (1,177   | )  |   |   | — |    |   |   | — |   |
| Net proceeds from (costs for) the issuance of common stock          |   |                | 90,269   |   |   |   | (5 | )  |   |   | — |    |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| Net cash provided by (used for) financing activities                |   |                | 18,781   |    |   |   | 16,090 |   |   |   | (17,246 | )  |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| Effect of exchange rate changes in cash and cash equivalents        |   |                | 179      |   |   |   | 195 |   |   |   | (40 | )  |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| Net increase (decrease) in cash and cash equivalents                |   |                | 4,715    |    |   |   | (5,299 | )  |   |   | 297 |    |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| Cash and cash equivalents, beginning of year                        |   |                | 3,036    |   |   |   | 7,751 |   |   |   | 2,452 |   |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| Cash and cash equivalents, end of year                              |   | $                   | 7,751    |   |   | $ | 2,452 |   |   | $ | 2,749 |   |
|                                                                |   |                |     |   |   |   |   |   |   |   |   |   |
| See accompanying Notes to Consolidated Financial Statements.        |

----

ANIMAL HEALTH INTERNATIONAL, INC.

Notes to Consolidated Financial Statements

----

| Buildings and improvements                                   |    | 10-40  |
|--------------------------------------------------------------|--------------|--------|
| Leasehold improvements (shorter of asset life or lease term) |    | 5-10   |
| Equipment:                                                   |    |   |
| Warehouse                                                    |    | 3-8    |
| Automotive                                                   |    | 3-8    |
| Computer hardware and software                               |    | 3-5    |
| Office                                                       |    | 3-8    |

----

----

|                     |   | Options |       |    | Weighted averageexercise prices |   |    | Weighted average fairvalue at grant date |   |
|--------------------------|--------|---------|------------|---------|--------------------------------------|--------|---------|----------------------------------------------------|--------|
| Balance at July 1, 2007  |   |    | 746,300    |    |                                 | $      | 11.03   |                                               |   | $ | 4.50 |   |
| Granted                  |   |    | 750,000    |    |                                 |   | 11.47   |                                               |   |   | 4.28 |   |
| Exercised                |   |    | —    |    |                                 |   | — |                                               |   |   | — |   |
| Forfeited                |   |    | (86,625    | )  |                                 |   | 11.01   |                                               |   |   | 4.48 |   |
|                     |   |    |       |    |                                 |   |    |                                               |   |   |   |   |
| Balance at July 1, 2008  |   |    | 1,409,675  |    |                                 |   | 11.27   |                                               |   |   | 4.38 |   |
| Granted                  |   |    | 750,000    |    |                                 |   | 2.37    |                                               |   |   | 0.70 |   |
| Exercised                |   |    | —    |    |                                 |   | — |                                               |   |   | — |   |
| Forfeited                |   |    | (1,145,500 | )       |                                 |   | 10.96   |                                               |   |   | 4.11 |   |
|                     |   |    |       |    |                                 |   |    |                                               |   |   |   |   |
| Balance at June 30, 2009 |   |    | 1,014,175  |    |                                 | $      | 5.03    |                                               |   | $ | 1.81 |   |

----

|                                                          |   | Year Ended June 30, |           |
|---------------------------------------------------------------|--------|---------------------|----------------|
|                                                          |   | 2007                |           |   | 2008 |   |   | 2009 |   |
| Net income (loss)                                             |   | $                   | 5,228          |   |   | $ | 11,101 |   |   | $ | (27,128 | )  |
| Dividend on redeemable preferred stock                        |   |                | (53,323        | ) |   |   | — |   |   |   | — |   |
| Deemed dividend upon conversion of redeemable preferred stock |   |                | (95,227        | )  |   |   | — |   |   |   |  — |   |
| Preferred stock participation in undistributed earnings       |   |                | (4,062         | )  |   |   | — |   |   |   |  — |   |
| Net income (loss) available to common shareholders            |   | $              |  (147,384 | )  |   | $  | 11,101 |   |   | $  | (27,128 | )  |
|                                                          |   |                |           |   |   |   |   |   |   |   |   |   |
| Basic weighted average shares outstanding                     |   |                | 11,329         |   |   |   | 24,330 |   |   |   | 24,330 |   |
| Dilutive effect of stock options                              |   |                | —        |   |   |   | — |   |   |   | — |   |
|                                                          |   |                |           |   |   |   |   |   |   |   |   |   |
| Diluted weighted average shares outstanding                   |   |                |  11,329   |   |   |   | 24,330 |   |   |   | 24,330 |   |
|                                                          |   |                |           |   |   |   |   |   |   |   |   |   |
| Basic earnings (loss) per share                               |   | $              |  (13.01   | )  |   | $  | 0.46 |   |   | $  | (1.12 | )  |
|                                                          |   |                |           |   |   |   |   |   |   |   |   |   |
| Diluted earnings (loss) per share                             |   | $              | (13.01         | )  |   | $  | 0.46 |   |   | $  | (1.12 | )  |

----

----

|                                 |   | June 30,2008 |   |   | June 30,2009 |   |
|--------------------------------------|--------|-------------------|--------|--------|-------------------|--------|
| Trade accounts receivable            |   | $                 | 75,141 |   |              | $      | 68,494 |   |
| Vendor rebate receivables            |   |              | 10,296 |   |              |   | 8,239 |   |
| Other receivables                    |   |              | 269    |   |              |   | 1,116 |   |
|                                 |   |              |   |   |              |   |   |   |
|                                 |   |              | 85,706 |   |              |   | 77,849 |   |
| Less allowance for doubtful accounts |   |              | (1,157 | )      |              |   | (3,408 | ) |
|                                 |   |              |   |   |              |   |   |   |
| Accounts receivable, net             |   | $                 | 84,549 |   |              | $      | 74,441 |   |

----

|                                                   |   | June 30,2008 |   |   | June 30,2009 |    |
|--------------------------------------------------------|--------|--------------|--------|--------|--------------|---------|
|  Note receivable from Sparhawk Laboratories, Inc. |   | $       | 325    |   |         | $  |  — |   |
|  Other notes receivable                           |   |         | 794    |   |         |    | 406 |   |
|                                                   |   |         |   |   |         |    |   |   |
|                                                   |   |         | 1,119  |   |         |    | 406 |   |
|  Less current portion of notes receivable         |   |         | (608   | )      |         |    | (126 | ) |
|  Notes receivable                                 |   | $       | 511    |   |         | $  | 280 |   |

|                                |   | June 30, 2008 |   |   | June 30, 2009 |   |
|-------------------------------------|--------|---------------|--------|--------|---------------|--------|
| Land                                |   | $             | 3,540  |   |          | $      | 3,461 |   |
| Buildings and improvements          |   |          | 4,525  |   |          |   | 4,378 |   |
| Leasehold improvements              |   |          | 3,655  |   |          |   | 3,749 |   |
| Construction in progress            |   |          | 112    |   |          |   | 26 |   |
| Equipment:                          |   |          |   |   |          |   |   |   |
|    Warehouse              |   |          | 2,234  |   |          |   | 2,359 |   |
|    Automotive             |   |          | 6,525  |   |          |   | 6,730 |   |
|    Office/software        |   |          | 3,995  |   |          |   | 5,392 |   |
|                                |   |          |   |   |          |   |   |   |
|                                |   |          | 24,586 |   |          |   | 26,095 |   |
| Less accumulated depreciation       |   |          | (7,490 | )      |          |   | (10,052 | ) |
|                                |   |          |   |   |          |   |   |   |
| Property, plant, and equipment, net |   | $             | 17,096 |   |          | $      | 16,043 |   |

----

|                                              |   | GrossCarryingamount |    |   | Accumulatedamortization |    |          | NetCarryingamount |   |
|---------------------------------------------------|--------|---------------------|---------|--------|-------------------------|---------|---------------|-------------------|--------|
| June 30, 2008:                                    |   |                |    |   |                    |    |          |              |   |
|    Goodwill                             |   | $                   | 82,642  |   |                    | $  |  — |              |   | $ | 82,642 |   |
|    Customer relationships               |   |                | 40,578  |   |                    |    | (9,150        | )                 |   |   | 31,428 |   |
|    Noncompete agreements                |   |                | 6,407   |   |                    |    | (1,771        | )                 |   |   | 4,636 |   |
|    Trademarks and tradenames            |   |                | 33,170  |   |                    |    |  — |              |   |   | 33,170 |   |
|                                              |   |                |    |   |                    |    |          |              |   |   |   |   |
|                                              |   | $                   | 162,797 |   |                    | $       | (10,921       | )            |   | $ | 151,876 |   |
|                                              |   |                |    |   |                    |    |          |              |   |   |   |   |
| June 30, 2009:                                    |   |                |    |   |                    |    |          |              |   |   |   |   |
|    Goodwill                             |   | $                   | 60,334  |   |                    | $  |  — |              |   | $ | 60,334 |   |
|    Customer relationships               |   |                | 40,578  |   |                    |    | (12,556       | )            |   |   | 28,022 |   |
|    Noncompete agreements                |   |                | 6,245   |   |                    |    | (2,809        | )            |   |   |  3,436 |   |
|    Trademarks and tradenames  |   |                | 33,170  |   |                    |    |  — |              |   |   | 33,170 |   |
|                                              |   |                |    |   |                    |    |          |              |   |   |   |   |
|                                              |   | $                   | 140,327 |   |                    | $       | (15,365       | )                 |   | $ | 124,962 |   |
|                                              |   |                |    |   |                    |    |          |              |   |   |   |   |

|                                                                              |   | June 30,2008 |          |   | June 30,2009 |    |
|-----------------------------------------------------------------------------------|--------|--------------|---------------|--------|--------------|---------|
| July 1 opening balance                                                            |   | $            | 78,598        |   |         | $       | 82,642 |   |
| Goodwill from acquisition of Kane                                                 |   |         | 9,008         |   |         |    |  — |   |
| Purchase price adjustments                                                        |   |         | 2,246         |   |         |    | 2,856 |   |
| Reclassification of goodwill to    identifiable intangible assets  |   |         | (7,210)       |   |         |    |  — |   |
| Goodwill impairment                                                               |   |         | —  |   |         |    | (25,164 | )  |
|                                                                              |   |         |          |   |         |    |   |   |
| June 30 ending balance                                                            |   | $       | 82,642        |   |         | $  | 60,334 |   |

|                                             |   | June 30,2008 |    |   | June 30,2009 |   |
|--------------------------------------------------|--------|--------------|---------|--------|--------------|--------|
| Credit agreement—Revolving credit facility |   | $            | 93,224  |   |         | $      | 79,245 |   |
| Credit agreement—Term Note                 |   |         | 44,100  |   |         |   | 43,650 |   |
| Liability for interest rate swap agreements      |   |         | 2,843   |   |         |   | 3,920 |   |
| Other                                            |   |         | 1,097   |   |         |   | 277 |   |
|                                             |   |         |    |   |         |   |   |   |
|                                             |   |         | 141,264 |   |         |   | 127,092 |   |
| Less current portion                             |   |         | (1,259  | )      |         |   | (7,179 | ) |
|                                             |   |         |    |   |         |   |   |   |
|                                             |   | $            | 140,005 |   |         | $      | 119,913 |   |

----

----

| Balance Sheet                                                                  |   | 2008    |    |    | 2009   |    |
|--------------------------------------------------------------------------------|--------|---------|---------|---------|--------|---------|
|                                                                           |   |    |    |    |   |    |
| Assets:                                                                        |   |    |    |    |   |    |
| Investment in subsidiaries                                                     |   | $       | 96,224  |    |   | $       | 70,381 |   |
|       Total assets                                    |   | $       | 96,224  |    |   | $       | 70,381 |   |
|                                                                           |   |    |    |    |   |    |   |   |
| Stockholders' equity:                                                          |   |    |    |    |   |    |   |   |
| Common stock                                                                   |   | $  | 243     |    |   | $  | 243 |   |
| Additional paid-in capital                                                     |   |    | 129,704 |    |   |    | 132,912 |   |
| Accumulated deficit                                                            |   |    | (31,725 | )       |   |    | (58,853 | ) |
| Accumulated other comprehensive loss                                           |   |    | (1,998  | )  |   |    | (3,921 | )  |
|      Total stockholders' equity                            |   | $  | 96,224  |    |   | $  | 70,381 |   |
|                                                                           |   |    |    |    |   |    |   |   |
| Statement of Operations                                                        |   | 2008    |    |    | 2009   |    |
|                                                                           |   |    |    |    |   |    |   |   |
| Expenses of parent                                                             |   | $       | (2,400  | )       |   | $       | (1,790 | ) |
| Tax benefit of parent                                                          |   |    | 960     |    |   |    | 716 |   |
| Net loss of parent before equity in earnings (loss) of subsidiaries  |   |    | (1,440  | )       |   |    | (1,074 | ) |
| Equity in earnings (loss) of subsidiaries                                 |   |    | 12,541  |    |   |    | (26,054 | )  |
|        Net income (loss)                              |   | $       | 11,101  |    |   | $       | (27,128 | )  |
|                                                                           |   |    |    |    |   |    |   |   |
| Statement of Cash Flows                                                        |   | 2008    |    |    | 2009   |    |
|                                                                           |   |    |    |    |   |    |   |   |
| Net loss of parent before equity in earnings (loss) of subsidiaries            |   | $       | (1,440  | )       |   | $       | (1,074 | ) |
| Net cash used for operating activities                                         |   |    | (1,440  | )       |   |    | (1,074 | ) |
|                                                                           |   |    |    |    |   |    |   |   |
| Investment in subsidiaries                                                     |   |    | 1,440   |    |   |    | 1,074 |   |
| Net cash provided by investing activities                                 |   |    | 1,440   |    |   |    | 1,074 |   |
|                                                                           |   |    |    |    |   |    |   |   |
| Dividends received                                                             |   |    | — |    |   |    | — |   |
| Dividends paid                                                                 |   |    | — |    |   |    | — |   |
| Net proceeds from issuance of common stock                                     |   |    | — |    |   |    | — |   |
| Net cash provided by financing activities                                      |   |    | — |    |   |    | — |   |
|                                                                           |   |    |    |    |   |    |   |   |
| Net change in cash                                                             |   | $       | — |    |   | $       | — |   |
|   F-19                                                               |

| Year ending June 30: |    |   |    |
|---------------------------|--------------|--------|---------|
| 2010                      |    | $      | 7,179   |
| 2011                      |    |   | 119,913 |
| 2012                      |    |   | — |
| 2013                      |    |   | — |
| 2014                      |    |   | — |
| Thereafter                |    |   | — |
|                      |    |   |    |
|                      |    | $      | 127,092 |

|                                                    |   |         |    |   | Fair Value |   |
|---------------------------------------------------------|--------|--------------|---------|--------|------------|--------|
|                                                    |   | June 30,2009 |    |   | Level 1    |   |   | Level 2 |   |   | Level 3 |   |
| Financial assets at cost:                               |   |         |    |   |       |   |   |   |   |   |   |   |
| Current portion of notes receivable                     |   | $       | 126     |   |       |   |   |   |   |   |   |   |   |
| Notes receivable, net of current portion                |   |         | 280     |   |       |   |   |   |   |   |   |   |   |
| Total                                                   |   | $            | 406     |   |       |   |   |   |   |   |   |   |   |
|                                                    |   |         |    |   |       |   |   |   |   |   |   |   |   |
| Financial assets at fair value:                         |   |         |    |   |       |   |   |   |   |   |   |   |   |
| Cash and cash equivalents                               |   | $            | 2,749   |   | $          | 2,749  |   | $ | — |   | $ | — |   |
| Total                                                   |   | $            | 2,749   |   | $          | 2,749  |   | $ | — |   | $ | — |   |
|                                                    |   |         |    |   |       |   |   |   |   |   |   |   |   |
| Financial liabilities at fair value:                    |   |         |    |   |       |   |   |   |   |   |   |   |   |
| Current portion of long-term debt (interest rate swaps) |   |         |    |   |       |   |   |   |   |   |   |   |   |
| $43,000 notional interest rate swap                     |   | $            | 1,771   |   |       | $      | — |   |   | $ | 1,771 |   |   | $ | — |   |
| $52,000 notional interest rate swap                     |   |         | 2,149   |   |       |   | — |   |   |   | 2,149 |   |   |   | — |   |
| Total                                                   |   | $            | 3,920   |   |       | $      | — |   |   | $ | 3,920 |   |   | $ | — |   |
|                                                    |   |         |    |   |       |   |   |   |   |   |   |   |   |   |   |   |
| Financial liabilities carried at historical proceeds:   |   |         |    |   |       |   |   |   |   |   |   |   |   |   |   |   |
| Current portion of long-term debt                       |   | $            | 3,259   |   |       |   |   |   |   |   |   |   |   |   |   |   |
| Long-term debt, net of current portion                  |   |         | 119,913 |   |       |   |   |   |   |   |   |   |   |   |   |   |
| Total                                                   |   | $            | 123,172 |   |       |   |   |   |   |   |   |   |   |   |   |   |

----

----

|                               |   | Year ended June 30, |   |
|------------------------------------|--------|---------------------|--------|
|                               |   | 2007                |   |   | 2008 |   |   | 2009 |   |
| Current income tax expense:        |   |                |   |   |   |   |   |   |   |
| Federal tax expense                |   | $                   | 4,963  |   |   | $ | 6,015 |   |   | $ | 1,280 |   |
| State and other tax expense        |   |                | 822    |   |   |   | 1,029 |   |   |   | 388 |   |
| Foreign tax expense                |   |                | 110    |   |   |   | 1,552 |   |   |   | 1,157 |   |
|                               |   |                |   |   |   |   |   |   |   |   |   |   |
|                               |   |                | 5,895  |   |   |   | 8,596 |   |   |   | 2,825 |   |
| Deferred income tax benefit        |   |                | (1,938 | ) |   |   | (1,188 | ) |   |   | (3,559 | ) |
|                               |   |                |   |   |   |   |   |   |   |   |   |   |
| Total income tax expense (benefit) |   | $                   | 3,957  |   |   | $ | 7,408 |   |   | $ | (734 | )  |

|                               |   | June 30, |    |
|------------------------------------|--------|----------|---------|
|                               |   | 2008     |    |   | 2009 |   |
| Deferred tax assets:               |   |     |    |   |   |   |
| Accounts receivable                |   | $        | 380     |   |   | $ | 1,291 |   |
| Accrued liabilities                |   |     | 2,057   |   |   |   | 2,166 |   |
| Merchandise inventories            |   |     | 724     |   |   |   | 613 |   |
| Stock options                      |   |     | 285     |   |   |   | 13 |   |
| Interest rate swaps                |   |     | 1,093   |   |   |   | 1,516 |   |
| Deferred lease incentives          |   |     | 627     |   |   |   | 542 |   |
|                               |   |     |    |   |   |   |   |   |
| Total deferred tax assets          |   | $   | 5,166   |   |   | $  | 6,141 |   |
|                               |   |     |    |   |   |   |   |   |
| Deferred tax liabilities:          |   |     |    |   |   |   |   |   |
| Prepaid expenses                   |   | $   | (478    | ) |   | $  | (711 | ) |
| Property, plant, and equipment     |   |     | (984    | ) |   |   | (931 | ) |
| Intangible assets                  |   |     | (27,304 | ) |   |   | (24,210 | ) |
|                               |   |     |    |   |   |   |   |   |
| Total deferred tax liabilities     |   | $   | (28,766 | ) |   | $ | (25,852 | ) |
|                               |   |     |    |   |   |   |   |   |
| Net deferred tax liabilities       |   | $        | (23,600 | ) |   | $ | (19,711 | ) |
|                               |   |     |    |   |   |   |   |   |
| Less current deferred income taxes |   |     | (2,682  | )  |   |   | (3,358 | )  |
|                               |   |     |    |   |   |   |   |   |
| Non-current deferred income taxes  |   | $   | (26,282 | )  |   | $  | (23,069 | ) |

----

|                                                            |   |  Year ended June 30, |    |
|-----------------------------------------------------------------|--------|---------------------------|---------|
|                                                            |   | 2007                      |    |   | 2008 |   |   | 2009 |   |
| Income tax expense (benefit) computed at federal statutory rate |   | $                         | 3,215   |   |   | $ | 6,477 |   |   | $ | (9,752 | )  |
| State taxes, net of federal benefit                             |   |                      | 495     |   |   |   | 726 |   |   |   | 108 |   |
| Permanent difference from goodwill impairment                   |   |                      | — |   |   |   | — |   |   |   | 7,589 |   |
| Other permanent differences                                |   |                      | 247     |   |   |   | 205 |   |   |   | 1,321 |   |
|                                                            |   |                      |    |   |   |   |   |   |   |   |   |   |
| Total income tax expense (benefit)                              |   | $                         | 3,957   |   |   | $ | 7,408 |   |   | $ | (734 | ) |
|                                                            |   |                      |    |   |   |   |   |   |   |   |   |   |
| Income taxes paid                                               |   | $                         | 9,157   |   |   | $ | 7,942 |   |   | $ | 2,144 |   |

|                         |   | Operatingleases |   |
|------------------------------|--------|-----------------|--------|
| Year ending June 30:         |   |            |   |
| 2010                         |   | $               | 4,646  |   |
| 2011                         |   |            | 3,938  |   |
| 2012                         |   |            | 3,420  |   |
| 2013                         |   |            | 3,019  |   |
| 2014                         |   |            | 1,487  |   |
| Thereafter                   |   |            | 2,130  |   |
|                         |   |            |   |   |
| Total minimum lease payments |   | $               | 18,640 |   |

----

|                                  |   | September 30, |    |   | December 31, |   |    | March 31, |   |   | June 30, |    |
|---------------------------------------|--------|---------------|---------|--------|--------------|--------|---------|-----------|--------|--------|----------|---------|
| (in thousands, except per share data) |   | 2007          |    |   | 2007         |   |    | 2008      |   |   | 2008     |    |
| Net sales                             |   | $             | 164,365 |   |         | $      | 203,230 |      |   | $      | 170,650  |    |   | $ | 178,297 |   |
| Gross profit                          |   |          | 28,631  |   |         |   | 39,904  |      |   |   | 32,835   |    |   |   | 35,687 |   |
| Income before income taxes            |   |          | 1,709   |   |         |   | 9,477   |      |   |   | 3,092    |    |   |   | 4,231 |   |
| Net income                            |   | $             | 1,021   |   |         | $      | 5,547   |      |   | $      | 1,877    |    |   | $ | 2,656 |   |
| Earnings per share:                   |   |          |    |   |         |   |    |      |   |   |     |    |   |   |   |   |
| Basic                                 |   | $             | 0.04    |   |         | $      | 0.23    |      |   | $      | 0.08     |    |   | $ | 0.11 |   |
| Diluted                               |   | $             | 0.04    |   |         | $      | 0.23    |      |   | $      | 0.08     |    |   | $ | 0.11 |   |
| Weighted average shares outstanding:  |   |          |    |   |         |   |    |      |   |   |     |    |   |   |   |   |
| Basic                                 |   |          | 24,330  |   |         |   | 24,330  |      |   |   | 24,330   |    |   |   | 24,330 |   |
| Diluted                               |   |          | 24,330  |   |         |   | 24,372  |      |   |   | 24,373   |    |   |   | 24,330 |   |
|                                  |   |          |    |   |         |   |    |      |   |   |     |    |   |   |   |   |
|                                  |   | September 30, |    |   | December 31, |   |    | March 31, |   |   | June 30, |    |
|                                  |   | 2008          |    |   | 2008         |   |    | 2009      |   |   | 2009     |    |
| Net sales                             |   | $             | 169,023 |   |         | $      | 184,477 |      |   | $      | 150,931  |    |   | $ | 162,517 |   |
| Gross profit                          |   |          | 30,300  |   |         |   | 32,268  |      |   |   | 25,329   |    |   |   | 26,057 |   |
| Income (loss) before income taxes     |   |          | 501     |   |         |   | 3,717   |      |   |   | (608     | )  |   |   | (31,472 | )  |
| Net income (loss)                     |   | $             | 284     |   |         | $      | 2,269   |      |   | $      | (324     | )  |   | $ | (29,357 | )  |
| Earnings (loss) per share:            |   |          |    |   |         |   |    |      |   |   |     |    |   |   |   |   |
| Basic                                 |   | $             | 0.01    |   |         | $      | 0.09    |      |   | $      | (0.01    | )  |   | $ | (1.21 | )  |
| Diluted                               |   | $             | 0.01    |   |         | $      | 0.09    |      |   | $      | (0.01    | )  |   | $ | (1.21 | ) |
| Weighted average shares outstanding:  |   |          |    |   |         |   |    |      |   |   |     |    |   |   |   |   |
| Basic                                 |   |          | 24,330  |   |         |   | 24,330  |      |   |   | 24,330   |    |   |   | 24,330 |   |
| Diluted                               |   |          | 24,330  |   |         |   | 24,330  |      |   |   | 24,330   |    |   |   | 24,330 |   |

----

|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number              |   |   | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                |   |
| 3.1(1)              |   |   | Form of Fourth Amended and Restated Certificate of Incorporation of Animal Health International, Inc.                                                                                                                                                                                                                                                                                                                                                                                                         |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 3.2(1)              |   |   | Form of Amended and Restated By-laws of Animal Health International, Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 4.1(2)              |   |   | Specimen Stock Certificate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.1(3)             |   |   | Livestock Products Agreement entered into on April 3, 2008 and effective as of December 22, 2007 by and between Pfizer Inc. and Walco International, Inc.                                                                                                                                                                                                                                                                                                                                                     |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.2(4)             |   |   | Livestock Products Agreement entered into on December 11, 2008 and effective as of January 1, 2009 by and between Pfizer Inc. and Walco International, Inc.                                                                                                                                                                                                                                                                                                                                         |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.3(1)             |   |   | Amended and Restated Credit Agreement, dated September 2006, by and among Animal Health International, Inc., each of the credit parties party thereto, each of the financial institutions party thereto, JPMorgan Chase Bank, N.A., as administrative agent for the Lenders and General Electric Capital Corporation as documentation agent for the lenders                                                                                                                                              |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.4(5)        |   |   | Second Amended and Restated Credit Agreement, dated October 2007, by and among Walco International, Inc., each of the credit parties party thereto, each of the financial institutions party thereto, JPMorgan Chase Bank, N.A., as administrative agent for the Lenders and General Electric Capital Corporation as documentation agent for the lenders                                                                                                                                                      |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.5(6)        |   |   | First Amendment to the Second Amended and Restated Credit Agreement, dated May 5, 2009, by and among Walco International, Inc., Kane Veterinary Supplies, Ltd., and each of the credit parties party thereto, each of the financial institutionsparty thereto, JPMorgan Chase Bank, N.A., as administrative agent for the U.S. lenders, JPMorgan Chase Bank, N.A. Toronto Branch, as administrative agent for the Canadian lenders, and U.S. Bank National Association as documentation agent for the lenders |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.6(1)   |   |   | Term Loan Agreement, dated September 2006, by and among Animal Health International, Inc., each of the credit parties party thereto and Wilmington Trust, as administrative agent for the lenders                                                                                                                                                                                                                                                                                                        |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.7(7)        |   |   | Term Loan Agreement, dated August 10, 2007, by and among Animal Health International, Inc., each of the credit parties party thereto and Wells Fargo Bank, National Association, as administrative agent for the lenders                                                                                                                                                                                                                                                                                      |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.8(2)        |   |   | 2007 Stock Option and Incentive Plan                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.9(2)        |   |   | Form of Incentive Stock Option Agreement under the 2007 Stock Option and Incentive Plan                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.10(2)            |   |   | Form of Non-Qualified Stock Option Agreement under the 2007 Stock Option and Incentive Plan for Company Employees                                                                                                                                                                                                                                                                                                                                                                                             |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.11(2)       |   |   | Form of Deferred Stock Unit Award under the 2007 Stock Option and Incentive Plan                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.12(11)      |   |   | Amendment to Deferred Stock Unit Award Agreement under the 2007 Stock Option and Incentive Plan                                                                                                                                                                                                                                                                                                                                                                                                               |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.13(2)       |   |   | Form of Restricted Stock Award Agreement under the 2007 Stock Option and Incentive Plan                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.14(1)       |   |   | Employment Agreement between Animal Health International, Inc. and James Robison, dated as of May 1, 1997                                                                                                                                                                                                                                                                                                                                                                                                     |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.15(1)       |   |   | Amendment No. 1 to Employment Agreement between Animal Health International, Inc. and James Robison, dated as of June 30, 2005                                                                                                                                                                                                                                                                                                                                                                           |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.16(9)       |   |   | Amendment No. 2 to Employment Agreement between Animal Health International, Inc. and James Robison, dated as of May 7, 2008                                                                                                                                                                                                                                                                                                                                                                                  |
|                |   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 10.17(8)            |   |   | Non-Compete Agreement between Walco International, Inc. and Kathy Hassenpflug dated as of March 10, 2000                                                                                                                                                                                                                                                                                                                                                                                                 |

----

| 10.18(8)   |   |   | Non Competition Addendum between Walco International, Inc. and Kathy Hassenpflug dated as of September 30, 2005                            |
|-----------------|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|            |   |   |                                                                                                                                            |
| 10.19(11)       |   |   | Amendment No. 2 to Agreement between Walco International, Inc. and Kathy Hassenpflug dated as of December 31, 2008                         |
|            |   |   |                                                                                                                                            |
| 10.20      |   |   | Amendment No. 3 to Agreement between Walco International, Inc. and Kathy Hassenpflug dated as of September 3, 2009                         |
|            |   |   |                                                                                                                                            |
| 10.21(1)        |   |   | Employment Agreement between Animal Health International, Inc. and William Lacey, dated as of August 15, 2003                         |
|            |   |   |                                                                                                                                            |
| 10.22(1)   |   |   | Amendment No. 1 to Employment Agreement between Animal Health International, Inc. and William Lacey, dated as of June 30, 2005             |
|            |   |   |                                                                                                                                            |
| 10.23(11)  |   |   | Amendment No. 2 to Employment Agreement between Walco International, Inc. and William Lacey dated as of December 31, 2008        |
|            |   |   |                                                                                                                                            |
| 10.24           |   |   | Amendment No. 3 to Employment Agreement between Walco International, Inc. and William Lacey dated as of September 3, 2009             |
|            |   |   |                                                                                                                                            |
| 10.25(1)   |   |   | Employment Agreement between Animal Health International, Inc. and Damian Olthoff, dated as of April 1, 2006                          |
|            |   |   |                                                                                                                                            |
| 10.26(11)  |   |   | Amendment No. 1 to Employment Agreement between Walco International, Inc. and Damian Olthoff dated as of December 31, 2008  |
|            |   |   |                                                                                                                                            |
| 10.27      |   |   | Amendment No. 2 to Employment Agreement between Walco International, Inc. and Damian Olthoff dated as of September 3, 2009            |
|            |   |   |                                                                                                                                            |
| 10.28(1)        |   |   | Form of Indemnification Agreement between Animal Health International, Inc. and each of its Directors and Executive Officers                    |
|            |   |   |                                                                                                                                            |
| 10.29      |   |   | Form of Amendment to Indemnification Agreement between Animal Health International, Inc. and each of its Directors and Executive Officers  |
|            |   |   |                                                                                                                                            |
| 10.30(7)   |   |   | Amended and Restated Plan for Compensation of Non-Employee Directors                                                                       |
|            |   |   |                                                                                                                                            |
| 10.31(2)   |   |   | Non-Employee Directors' Deferred Compensation Program                                                                                      |

| 21.1       |   |   | List of Subsidiaries                                                                                                                                           |
|------------|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       |   |
| 23.1       |   |   | Consent of Grant Thornton LLP                                                                                                                        |
|       |   |   |                                                                                                                                                           |
| 23.2  |   |   | Consent of KPMG LLP                                                                                                                                       |
|       |   |
| 24.1       |   |   | Powers of Attorney (included on signature page hereto)                                                                                                         |
|       |   |
| 31.1       |   |   | Rule 13a-14(a)/15d-14(a) Certification, executed by James C. Robison, Chief Executive Officer, President and Director                                     |
|       |   |
| 31.2       |   |   | Rule 13a-14(a)/15d-14(a) Certification, executed by William F. Lacey, Chief Financial Officer                                                             |
|       |   |
| 32.1       |   |   | Section 1350 Certifications, executed by James C. Robison, Chief Executive Officer, President and Director, and William F. Lacey, Chief Financial Officer |

----

----

| (1)    | Incorporated by reference to Amendment No. 2 to our Registration Statement on Form S-1 (File No. 333-137656) filed on December 13, 2006     |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                        |
| (2)    | Incorporated by reference to Amendment No. 4 to our Registration Statement on Form S-1 (File No. 333-137656) filed on January 16, 2007 |
|   |                                                                                                                                        |
| (3)    | Incorporated by reference to our Current Report on Form 8-K filed on April 7, 2008                                                          |
|   |                                                                                                                                        |
| (4)    | Incorporated by reference to our Current Report on Form 8-K filed on December 16, 2008                                                      |
|   |                                                                                                                                        |

| (5)       | Incorporated by reference to our Quarterly Report on Form 10-Q filed on February 7, 2008     |
|-----------|----------------------------------------------------------------------------------------------|
|      |                                                                                         |
| (6)       | Incorporated by reference to our Current Report on Form 8-K filed on December 16, 2008       |
|      |                                                                                         |
| (7)  | Incorporated by reference to our Annual Report on Form 10-K filed on September 9, 2008  |
|      |                                                                                         |

| (8)        | Incorporated by reference to our Quarterly Report on Form 10-Q filed on November 7, 2007 |
|------------|------------------------------------------------------------------------------------------|
|       |                                                                                     |
| (9)        | Incorporated by reference to our Quarterly Report on Form 10-Q filed on May 8, 2008      |
|       |                                                                                     |
| (10)       | Incorporated by reference to our Current Report on Form 8-K filed on October 5, 2007     |
|       |                                                                                     |
| (11)  | Incorporated by reference to our Current Report on Form 8-K filed on January 2, 2009     |